




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C12Q 1/68, C12P 19/34, C12N 15/10</b>	A1	(11) International Publication Number: <b>WO 96/38591</b> (43) International Publication Date: <b>5 December 1996 (05.12.96)</b>
--	----	---

(21) International Application Number: <b>PCT/US96/08501</b>	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>3 June 1996 (03.06.96)</b>	
(30) Priority Data:	
08/459,046 2 June 1995 (02.06.95) US	
08/462,355 5 June 1995 (05.06.95) US	
08/487,112 7 June 1995 (07.06.95) US	
60/006,809 15 November 1995 (15.11.95) US	
08/566,334 1 December 1995 (01.12.95) US	
(71) Applicant: INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).	Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventor: GUEGLER, Karl, J.; 1048 Oakland Avenue, Menlo Park, CA 94025 (US).	
(74) Agent: GLAISTER, Debra, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	

## (54) Title: IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES



## (57) Abstract

A method for obtaining longer cDNA sequences is provided. The method utilizes a known genomic DNA sequence or a partial cDNA sequence, such as can be obtained from GenBank partial cDNAs. Two PCR primers are designed to correspond to the ends of the known partial sequence and to anneal to DNA in a cDNA library so as to initiate extension away from the known cDNA and the other primer. The primers are added to a cDNA library with appropriate enzymes and extend through additional DNA sequence to produce PCR products, which are subsequently purified and sequenced to provide new sequences. The new sequences are then compared with the known partial cDNA sequence for areas of overlap, and the sequence is extended beyond the overlapping areas to provide longer DNA sequence.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Malta	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES

## TECHNICAL FIELD

The present invention is in the field of molecular biology  
5 and more particularly, in the field of recombinant DNA technology.

## BACKGROUND ART

PCR has become a widely used nucleic acid amplification technique since it was first presented by Kary Mullis at the Cold 10 Spring Harbor Symposium (Mullis K et al (1986) Cold Spring Harbor Symp Quant Biol 51: 263-273). PCR requires that a pair of primers be generated from known sequences. However, in many cases, sequence is available only from one end of a DNA segment. Several methods have been developed to sequence an entire gene once a 15 partial nucleotide sequence is available. As more partial cDNA sequences become available in the world's genetic databanks, more efficient and economical methods will be sought for then obtaining the complete gene.

PCR has become a widely used technique to complete genes for 20 which a partial sequence is already known. Gene-specific primers and primers located in the vector into which the cDNAs have been cloned are used for this purpose. However, this method is limited by the use of primers complementary to vector sequence which is common to all clones in the library. This results in an abundance 25 of non-specific PCR-products which have to be cloned and sequenced. Multiple rounds of amplifications with nested primers might be required. These additional operations increase the incorporation of errors.

Gobinda, Turner and Bolander (1993) in PCR Methods and 30 Applications 2:318-22 disclose "restriction-site PCR" as a direct method of retrieving unknown sequence which is adjacent to a known locus by using universal primers. First, genomic DNA is amplified in the presence of restriction site oligonucleotides and a primer

specific to the known region. Next, those products are subjected to a second round of PCR with the same restriction site oligonucleotides and another specific primer internal to the first one. Subsequently, the products of the last round of PCR are 5 transcribed with an appropriate RNA polymerase and sequenced with a reverse transcriptase and an end-labeled specific primer internal to the second specific PCR primer. Gobinda et al. present data concerning Factor IX for which they identified a 10 conserved stretch of 20 nucleotides in the 3' noncoding region of the gene.

Inverse PCR is the first method that reported successful acquisition of unknown sequences starting with primers based on a known region (Triglia T, Peterson MG, and Kemp DJ (1988) Nucleic Acids Res. 16:8186). Inverse PCR employs a strategy in which 15 several restriction enzymes are used to generate a suitable fragment in the known region. The segment is then circularized by intramolecular ligation and used as a PCR template with divergent primers created from the known region. However, the requirement of multiple restriction enzyme digestions followed by multiple 20 ligations (even before PCR is started) make the procedure slow and expensive (Gobinda et al. *Supra*).

Capture PCR, first disclosed by Lagerstrom M, Parik J, Malmgren H, Stewart J, Patterson U and Landegren U (1991) PCR Methods Applic. 1:111-19, is a method for PCR amplification of DNA 25 fragments adjacent to a known sequence in human and YAC DNA. As noted by Gobinda et al. *supra*, that method also requires multiple restriction enzyme digestions and ligation of an engineered double-stranded primer before PCR. Although the restriction and ligation reactions are carried out simultaneously in this method, 30 the requirement of extension reaction, immobilization of the extended product, two rounds of PCR and purification of template prior to sequencing render it cumbersome and time consuming as well.

Walking PCR, disclosed by Parker JD, Rabinovitch PS, and Burmer GC (1991) Nucleic Acids Res 19:3055-60, teaches a method for targeted gene walking via PCR. Although this method also permits retrieval of unknown sequence, Gobinda et al, *supra*, note 5 that it requires oligomer-extension assay followed by identification and gel purification of the desired band prior to sequencing. Such extra steps again limit the applicability of the method.

The enzymes originally used in PCR were limited in their 10 ability to reliably amplify long pieces of nucleic acids over 3kb. One of the explanations for this limitation seems to be the misincorporation of nucleotides resulting in non-basepairing mismatches which these enzymes often fail to extend.

Only the mixture of two enzymes, rTth DNA-Polymerase and 15 Vent, the latter of which has so-called "proofreading" activity, and the optimization of amplification conditions finally overcame this limitation and made amplification of pieces of DNA of up to 40kb possible.

The most common way to identify genes expressed in a certain 20 tissue at a certain time is the isolation of the mRNA of that particular tissue and the conversion of this mRNA into so-called cDNA (complementary DNA). This cDNAs are subsequently cloned into a vector (plasmid or Lambda) and amplified by transfection into E.coli cells resulting in a so-called cDNA library.

First and most important to researchers attempting to obtain 25 a complete gene is that the enzymes used in converting mRNA into cDNA are limited in their ability to produce complete copies of the existing mRNAs. This requires the researcher to isolate multiple cDNA clones of the gene of interest using specific probes 30 and analyze each of these isolates for a complete cDNA of the gene of interest. This process is called screening of cDNA libraries.

A major problem facing molecular biologists is finding the most efficient method to use to obtain a full-length cDNA from a

partial sequence. Such sequences are appearing with increasing frequency in GenBank, from commercial cDNA libraries and privately prepared libraries. The inventive method disclosed herein is a contribution to that art.

5

#### DISCLOSURE OF THE INVENTION

An improved method for extending the DNA sequence of a known fragment of DNA sequence is provided. The method may be used for extending known DNA sequences of genomic or cDNA origin. The method utilizes the polymerase chain reaction (PCR) and includes 10 the steps of:

a) combining a first and second PCR primer with nucleic acid from a cDNA library, or pools of cDNA libraries, expected to contain said partial cDNA, or said partial cDNA that has been extended, or a genomic library, under conditions suitable for 15 synthesis of nucleic acid PCR products from the first and second primers, wherein said first and second primers are capable of annealing to opposite strands of the partial cDNA or genomic DNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA 20 polymerase in an antisense direction and the second primer is capable of being extended in a sense direction,

b) purifying the PCR products, and  
c) identifying extended nucleotide sequences derived from 25 said partial cDNA or said genomic DNA. In one embodiment of the present invention, the method of identifying the extended nucleotide sequences comprises nucleic acid sequencing. In another embodiment of the present invention, the method proceeds with repeating steps 6a through 6c on the nucleotide sequences identified in step 6c.

30 In another embodiment of the present invention, there is a method for extending the nucleotide sequence of a partial complementary DNA (cDNA) using polymerase chain reaction (PCR), comprising the steps of a) combining a first and second PCR primer

with nucleic acid from a cDNA library, or pools of cDNA libraries, expected to contain said partial cDNA, or said partial cDNA that has been extended, or a genomic DNA library, under conditions suitable for synthesis of nucleic acid PCR products from the first and second primers, wherein said first and second primers are capable of annealing to opposite strands of the partial cDNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA polymerase in an antisense direction and the second primer is capable of being 5 extended in a sense direction,  
10 b) purifying the PCR products,  
c) ligating the purified PCR products under conditions suitable for the formation of circular, closed nucleic acid,  
d) transforming a host cell with the circular, closed nucleic acid and culturing the transformed host cell under conditions 15 suitable for growth,  
e) recovering said circular closed nucleic acid from the cultured, transformed host cell, and  
f) identifying extended nucleotide sequences derived from 20 said partial cDNA or said genomic DNA.

The present invention also provides a method for extending known genomic DNA sequences which may be used for the detection and amplification of 5' untranslated nucleotide sequences and/or promoter sequences.

25 Also provided is an isolated DNA molecule comprising SEQ ID NO:11, the DNA for a novel human purinergic P2U receptor.

Also provided is an isolated DNA molecule comprising SEQ ID NO:12, the DNA for a novel human C5a-like seven transmembrane receptor.

30 These and other objects, advantages and features of the present invention will become apparent to those persons skilled in the art upon reading the details of the structure, synthesis, formulation and usage as more fully set forth below, reference

being made to the accompanying figures forming a part hereof.

#### BRIEF DESCRIPTION OF DRAWINGS

Figure 1 is a flow chart of the steps in the inventive method.

5 Figure 2 shows a typical plasmid obtained from the excision process of a lambdaZAP cDNA library. Typically 250-300 base pairs of the sequence are obtained in the high-throughput sequence operation. The clone is partially sequenced from the 5' end with T3 as a sequencing primer.

10 Figure 3 is a representation of the next step, in which pBLUESCRIPT SK plasmids in a cDNA library are used as a template and the two specially designed primers (XLR and XLS) amplify plasmids containing the gene of interest. Only plasmids containing priming sites for both XL-PCR primers and the gene of 15 interest will be amplified during the XL-PCR reaction.

20 Figure 4 is a representation of the amplified DNA segments which have been obtained through the XL-PCR reaction and consequently purified after separating the products on an agarose gel. For best results, the cDNA library used as a template should 25 be synthesized by random priming to assure the availability in this step of different amplified length of DNA (3' end) between the XLS priming site and the T7 priming site in the vector. The length of the 5' end (between the XLR priming site and the T3 priming site) in the vector will vary in size depending on how much of the mRNA of the gene of interest had been converted into cDNA during the cDNA library synthesis.

25 Figure 5 shows how the purified DNA segments containing the plasmid and the gene of interest are religated to form a circular plasmid and transformed into bacteria for amplification. Here 30 chemically competent E. coli cells were transformed and grown on petri dishes containing LB agar and 25 mg/L carbenicillin (2XCarb) for antibiotic selection.

Figure 6 shows schematically how pure samples of clones were

obtained from the different E. coli colonies grown in the procedure shown in Figure 5 (also Step 1 purification, Step 2 religation and Step 3 transformation in Figure 6). These clones are screened in Step 4 for additional sequence of the gene of interest at the 5' end. For this purpose the clones were analyzed by a PCR reaction employing the XLR primer and the T3 vector primer. The size of the resulting product will indicate how much additional sequence upstream of the XLR priming site each clone contains.

Figures 7A through 7H show the results of the inventive method, in which a partial sequence from Incyte clone 14770, which was similar to heat shock protein 90, was successively sequenced to obtain a full-length cDNA.

Figures 8A through 8F show the results of the inventive method, in which a partial sequence from Incyte clone 87058 which was similar to cathepsin was successively sequenced to obtain extensions of the cDNA.

#### **MODES FOR CARRYING OUT THE INVENTION**

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference herein.

Before the present compounds, variants, formulations and methods for making and using such are described, it is to be understood that this invention is not limited to the particular compounds, variants, formulations or methods described, as such enzymes, formulations and methodologies may, of course, vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of protection will be limited only by the appended claims.

In the specification and appended claims, the singular forms

"a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a high-fidelity PCR enzyme" includes mixtures of such enzymes and any other enzymes fitting the stated criteria, reference to the 5 method includes reference to one or more methods for obtaining full-length cDNA sequences which will be known to those skilled in the art or will become known to them upon reading this specification.

The present method provides a way to utilize a genomic 10 DNA library or a plasmid cDNA library (either obtained by cloning cDNAs directly into a plasmid vector or by converting a Lambda library into a plasmid library by known methods e.g. Lambda ZAP excision or Lambda ZIPLOCK conversion) which has been used for sequencing cDNAs, as a source to obtain much longer DNAs and in 15 certain cases complete genes of partially known DNA sequences. The steps disclosed herein are based on cDNA libraries but equally apply to genomic DNA libraries.

This new method utilizes PCR kits which enable the researcher to amplify long pieces of DNA. The XL-PCR amplification kit 20 (Perkin-Elmer) was employed. However, equivalent products may be available from other major suppliers. This novel method allows one person to process multiple genes (up to 96 genes) at a time and obtain extended or complete sequence (possibly full-length) of the cDNAs of interest within 6-10 days. This compares very favorably 25 with current competitive methods like screening with labelled probes which allow one worker to process only about 3-5 genes and obtain initial results in 14-40 days. This represents an increase in throughput of at least 1000%.

This increased efficiency is possible because of the 30 inventive combination of steps shown in the flow chart (Figure 1). First, primer design and synthesis (based on a known partial sequence) can be performed in about two days. The PCR amplification can be performed in 6-8 hours. Multiple libraries

can be pooled and therefore screened at the same time. The next steps of purification and ligation take about one day. Then transformation and growing up the bacteria take one day. Then screening for clones with additional sequence of the genes of interest by PCR takes approximately five hours. The next steps of DNA preparation and sequencing of the selected clones can be performed in about one day. This totals 6-7 days. At the end of this time, one has usually obtained a much longer cDNA sequence, assuming such a longer cDNA existed in the libraries than what was initially sequenced. If the new sequence is a complete gene, then the goal has been reached. If the complete sequence has not been obtained, one still has a much longer sequence than before, and this longer sequence can be used to design primers to repeat the procedure on the same or another library. The choice of library is up to the researcher, but a preferred library is one that has been size-selected to include only larger cDNAs.

This method presumes that one already has partial cDNA sequences, either from a publicly available database or the scientist's own earlier research, including but not limited to earlier preparation of a cDNA library whose cDNAs have been partially sequenced. The cDNA library may have been prepared with oligo dT or random primers. The difference between oligo dT and randomly primed libraries is that a randomly primed library will have more sequences which contain 5' ends of cDNAs. A randomly primed library may be particularly useful for further work when the oligo dT library does not yield a complete gene. Random priming of the library also helps yield more cDNA sequences of different lengths. Library preparation techniques which promote longer insert sizes will in turn permit the sequencing of more complete cDNAs. Obviously, the larger the protein, the less likely it is that the complete cDNA will be found in a single plasmid.

Figure 2 shows a typical plasmid containing a cDNA which had

been partially sequenced from the 5' end with T3 as a primer. The top darkened portion represents the insert containing the gene of interest.

5      Step 1: PCR-amplification of cDNA-clones containing the gene of interest

The first step of this method requires the design of two primers based on the known sequence. The known sequence can be obtained by those skilled in the art either by a wet lab method or from the many publicly available DNA databases. One primer is 10 synthesized to be extended in an antisense direction (XLR) and the other in the sense direction (XLS or XLF). In effect, the primers are designed to anneal to either end of the known sequence and to be extended "outward" from there to generate amplicons containing new, unknown sequences of the genes of interest. This is 15 different from typical PCR, in which the primers are designed to amplify a known sequence in a direction "inward" toward each other.

The primers need to be designed in a way displaying optimal criteria for extra long PCR. A program like Oligo 4.0s (National 20 Biosciences, Inc., Plymouth MN) can be employed for this purpose. In general primers should be 22-30 nucleotides in length, consist of a GC content of 50% or more and anneal at 68°C-72°C to the target. Hairpin structures and primer-primer dimerizations must be avoided.

25      Primers varying from the conditions described above may result in amplification of the desired targets providing extension conditions have been adjusted.

Figure 3 shows the next step, in which a cDNA library is used as a template and the two primers (XLR and XLS) amplify plasmids 30 containing the gene of interest. In this step, it is very helpful to use PCR enzymes which provide high fidelity and copy long sequences, such as that provided in the XL-PCR kit (Part No. N808-0182, Perkin Elmer, Applied Biosystems, Foster City, CA).

Generally, kit instructions should be followed, including suggestions to optimize concentrations of various reagents. In the examples disclosed *infra*, 25pMol of each primer worked well. Template (plasmid library) concentrations can be varied (see Examples *infra* for details). It is essential to thoroughly resuspend the enzyme in solution prior to use, especially if the solution has been stored at -20°C. If the enzyme is not adequately resuspended, its effectiveness is impaired. The preferred system is setup initially in two layers, employing Ampliwax® PCR Gems. However, efficiency can be increased by avoiding the use of these Gems and initiating amplification by using the "hot-start" technique by adding Magnesium, which is essential for amplification, at 82° C.

Although various cycling conditions are detailed in the examples *infra*, the following cycling conditions have been found to be optimal with the MJ PCT200 thermocycler (MJ Research, Watertown, MA). Times and temperatures may be varied to optimize conditions in different thermocyclers.

Step 1 94° for 60 sec (initial denaturation)  
20 Step 2 94° for 15 sec  
Step 3 65° for 1 min  
Step 4 68° for 7 min  
Step 5 Repeat step 2-4 for 15 additional times  
Step 6 94° for 15 sec  
25 Step 7 65° for 1 min  
Step 8 68° for 7 min + 15 sec/cycle  
Step 9 Repeat step 6-8 for 11 additional times  
Step 10 72° for 8 min  
Step 11 4° for 0.00 sec (to hold at 4°)

30 At the end of these 28 cycles, 50 µl of the reaction mix is removed; on the remaining reaction mix, an additional 10 additional cycles are run, as outlined below:

Step 1 94° for 15 sec  
35 Step 2 65° for 1 min  
Step 3 68° for (10 min + 15 sec)/cycle  
Step 4 Repeat step 1-3 for 9 additional times  
Step 5 72° for 10 min

Next a 5-10  $\mu$ l aliquot of the reaction mixture can be analyzed on a mini-gel to determine which reactions were successful.

Step 2: Purification of amplicons containing the gene of interest

5       Figure 4 is a graphical representation of the amplified cDNA segments which have been separated on an agarose gel. Note that there are a variety of lengths of cDNA. Although the rest of the method could be performed using all extended cDNA species, the method can proceed optionally after selecting the largest products 10 (likeliest to provide the remainder of the full-length gene). Some of the larger species may in fact be hybrid clones which contain two cDNA inserts as a result of malfunction during the cDNA library construction which may represent an incomplete digestion with the restriction enzyme at the end of the cDNA 15 synthesis. Such amplified hybrid clones, also called chimera, could result in overlooking the correct targeted extensions.

Successful reaction products should be purified on an agarose gel (preferentially low agarose concentrations 0.6-0.8% should be used) or other appropriate method. An appropriate volume of 20 reaction mixture should be loaded to obtain good separation of the products and to separate them from the plasmid library (template) still in the reaction mixture. Contamination with the template cDNA library will result in transformants which don't contain the desired gene and will require an extensive screening of many 25 colonies. The bands representing the genes of interest are then cut out of the gel and purified using a method like the QIAQuick gel extraction kit (Qiagen, Inc., Chatsworth, CA).

Step 3: Cloning of amplicons containing the gene of interest

30       Eventual overhangs are converted into blunt ends to facilitate religation and cloning of the products. For this purpose, Klenow enzyme (3 units/reaction mixture) and dNTP's (0.2 mM final concentration) are added and the reaction is incubated at room temperature for 30 min. The Klenow enzyme is then

inactivated by incubating the reaction at 75° for 15 min.

The products are then ethanol precipitated and redissolved in 13  $\mu$ l of ligation buffer containing 1 mM ATP. 1ml T4-DNA ligase (15 units) and T4 Polynucleotide kinase (5 units) are added and 5 the reaction is incubated at room temperature for 2-3 hours or overnight at 16°C.

3 $\mu$ l of the ligation mixture are transformed into 40ml of competent E.coli cells (prepared with a standard protocol). 80 $\mu$ l of SOC medium are added and after 1 hour of recovery of the cells 10 at 37°C the whole transformation mixture is plated on LB-agar 2XCarb-containing petri plates.

Step 4: Screening of cloned products

The next day 8 or 12 colonies are randomly picked from each plate and grown in individual wells of a sterile 96-well 15 microtiter plate (e.g. 96 Well Cell Culture Cluster, Catalog No. 3799, Costar Corp., Cambridge, MA 02140). Each well contains 150ml of LB/2XCarb medium. Thus, each row of the microtiter plate contains twelve clones from the same extension reaction. The cells are grown over night at 37°C.

20 The next day, 5  $\mu$ l of these overnight cultures are transferred into a non-sterile 96-well plate (Falcon 3911 Microtest III™, Flexible Assay Plate, Becton Dickinson, Oxnard, CA) and diluted 1:10 with water. 5 $\mu$ l of each dilution are then transferred into a PCR array (e.g., Cycleplate, Robbins Scientific Corp., Sunnyvale, 25 CA). To obtain a 1X final concentration of PCR reagents, 15  $\mu$ l of a 1.33X concentrated PCR mix are added to each well. Another way of efficient screening for extension products is the multiplex PCR method where multiple specific primers are pooled and submitted to the same reaction, therefore increasing the efficiency of setting 30 up the screening mixtures. Addition of the PCR-template (individual cultures) has been improved by the use of a 96-pin tool with which an aliquot of all 96 cultures grown as described

above can be transferred into the PCR-screening mix in a matter of 1-2 minutes.

For PCR amplification, the final concentrations are 1X for PCR mix, 5  $\mu$ M of each of a vector primer and one or both of the 5 gene specific primers used for the original extension reaction and 0.75 units of Taq polymerase are added to each well.

Amplification generally was performed using the following conditions:

Step 1 94°C for 60sec  
10 Step 2 94°C for 20sec  
Step 3 55°C for 30sec  
Step 4 72°C for 90sec  
Step 5 repeat steps 2-4 for an additional 29 times  
Step 6 72°C for 180sec  
15 Step 7 4°C for ever

Aliquots of these PCR reactions are run on agarose gels together with molecular weight markers. The size of the resulting PCR products will allow direct determination of how much additional sequence the selected clones contain compared to the 20 original partial cDNA. The efficiency of the method has been further improved by using the resulting PCR-products directly for sequencing thus avoiding the necessity of preparing plasmids.

The appropriate clones are selected and grown for plasmid preparation and sequencing.

25 Plasmid preparations are made with standard kits familiar to those skilled in the art. Examples include the PROMEGA Magic MINIPREP and the AGTC alkaline lysis kit.

Sequencing is performed employing standard automated ABI 30 sequencing equipment and protocols using either dye-primer or dye-terminator kits.

Sequence processing and assemblage of the sequencing data are performed using standard ABI software, including INHERIT™ analysis and the Power assembler.

**INDUSTRIAL APPLICABILITY****Example 1**

For the initial method evaluation, a known gene was selected. A partial sequence of the human 90-kDa heat-shock protein gene (HUMHSP90, accession M16660) had been identified in a THP-1 library. This partial sequence (Incyte clone T-014201) initiated at base 1127 of the sequence with accession number M16660.

**1.1 Primer design**

Two primers were designed to perform the method described in the invention.

Primer 1 (XLR) 5' AGC TGT CCA TGA TGA ACA CAC G 3'  
(1180-1159)

Primer 2 (XLS) 5' AAT AGG CAC CAC ACC AAC TGA G 3'  
(2011-2032)

**1.2 Template preparation**

A THP-1 cDNA library constructed into the LambdaZAP vector (Stratagene) was converted into a plasmid library following the mass excision protocol. Plasmids of the excised libraries were prepared using the Quiagen Midi plasmid purification kit.

**1.3 XL-PCR reaction set-up**

The extension reactions were prepared following the instructions provided with the GeneAmp XL PCR Kit (Part No. N808-0182) from Perkin Elmer. A two layer system was set up as follows:

The lower reagent mix was prepared by pipetting the following components into a 0.2ml MicroAmp reaction tube.

**Lower reagent mix preparation:**

Water 13.6  $\mu$ l

3.3X buffer 12.0  $\mu$ l

dATP (10mM) 2.0  $\mu$ l

dCTP (10mM) 2.0  $\mu$ l

dGTP	(10mM)	2.0 $\mu$ l
dTTP	(10mM)	2.0 $\mu$ l
Primer XLS	(50 $\mu$ M)	1.0 $\mu$ l
Primer XLR	(50 $\mu$ M)	1.0 $\mu$ l
5	Mg (OAc) 2 (25mM)	4.4 $\mu$ l

---

Total lower reagent mix 40.0  $\mu$ l

One AmpliWax™ gem was added to the tube. The wax was melted  
10 by incubating the reaction tubes at 75°C for 5 minutes. Then the  
tubes were cooled down to 4°C.

Upper reagent mix preparation:

3.3X buffer	18.0 ml
15 rTth DNA Polymerase	2.0 ml

---

Total upper enzyme mix 20.0  $\mu$ l

20  $\mu$ l of the enzyme/buffer mix are added to each tube and  
kept separated from the lower mix by the wax layer.

Addition of template:

The template DNA (excised library) was diluted to an  
appropriate concentration in water and then added to the upper  
mix. Mixing of the components is not necessary.

25  
Template (6.25ng/ml) 40.0  $\mu$ l

---

Final volume 100.0  $\mu$ l

30 1.4 XI-PCR amplification

For amplification the following protocol was employed:

Step 1 94° for 60 sec (initial denaturation)  
Step 2 94° for 15 sec  
Step 3 65° for 1 min  
Step 4 68° for 7 min  
5 Step 5 Repeat step 2-4 for 15 additional times  
Step 6 94° for 15 sec  
Step 7 65° for 1 min  
Step 8 68° for 7 min + 15 sec/cycle  
Step 9 Repeat step 6-8 for 11 additional times  
10 Step 10 72° for 8 min  
Step 11 4° for 0.00 sec (to hold at 4°)

### 1.5 Purification of amplified products

30  $\mu$ l of the amplified products were run on a 0.7% agarose  
15 gel for 16 hours. Visible DNA bands were then cut out and purified  
using the QIAquick gel purification kit.

### 1.6 Cloning of amplified products

Klenow enzyme (3 units/reaction) and dNTP's (0.2mM final  
concentration) were added and the reactions were incubated at room  
20 temperature for 30 min followed by incubation at 75° C for 15 min.  
The products were then ethanol precipitated and redissolved in 13  
 $\mu$ l of ligation buffer containing 1mM ATP. T4-DNA ligase (15 units)  
and T4 Polynucleotide kinase (5 units) were added, and the  
reaction was incubated at room temperature for 3 hours.

25 3 $\mu$ l of the ligation mixture were transformed into 40 ml of  
competent E.coli cells. After heatshocking the cells at 42° C for  
45 seconds, 80  $\mu$ l of SOC medium were added, and the cells were  
allowed to recover at 37° C for 1 hour. The whole transformation  
mixture then was plated on LB-agar/2XCarb-containing petri dish  
30 plates.

### 1.7 Screening of cloned products

The next day 10 colonies were randomly picked and grown

overnight in Falcon 2059 tubes (Becton Dickinson, Oxnard, CA) containing 3 ml of LB-broth with 2X Carb.

5        5  $\mu$ l of the cultures were diluted 1:10 with water and 5 ml of this dilution were transferred into MicroAmp<sup>TM</sup> PCR tubes (Perkin Elmer, Applied Biosystems, Foster City, CA).

15  $\mu$ l of a 1.33X concentrated PCR mix were added to each well.

The 1.33 x concentrated PCR mix contained the following components:

10	10X PCR-buffer	2.0 $\mu$ l
	2mM dNTPs	2.0 $\mu$ l
	M13 rev primer (0.01mM)	1.0 $\mu$ l
	Primer 2 (XLR, 0.01mM)	1.0 $\mu$ l
	Taq Polymerase	0.15 $\mu$ l
15	Water	8.85 $\mu$ l

---

Final Volume	15.0 $\mu$ l
--------------	--------------

The PCR cycling conditions were chosen as follows:

Step 1	94° C for 60sec
20	Step 2    94° C for 20sec
	Step 3    55° C for 30sec
	Step 4    72° C for 90sec
	Step 5    repeat steps 2-4 for an additional 29 times
	Step 6    72° C for 180 sec
25	Step 7    4° C for ever

Aliquots of the amplified products were run on a 0.8% agarose gel in parallel with the 1 kb DNA ladder (Life Technologies, Gaithersburg, MD 20897). Appropriate plasmids containing different size inserts were selected for sequencing analysis.

30        1.8 Sequencing analysis of cloned products

The DNA of the selected clones was prepared using the

WizardTM Minipreps DNA Purification System (Promega Corporation, Madison, WI) following the instructions of the manufacturer. Sequencing reactions were performed using the PRISM™ Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Part No 401628, 5 Perkin Elmer, Applied Biosystems, Foster City, CA).

#### 1.9 Analysis of sequenced products

Three clones were selected for sequencing (14201.3, 14201.5, 14201.13). The sequences obtained (SEQ ID NOS:3-5, respectively) were aligned using the DNASIS Multiple sequence alignment program.

10 Clone 14201.3 initiated at base 24 of the published sequence (HUMHSP90), clone 14201.5 initiated at base 13 of the published sequence and clone 14201.13 initiated at base 538 of the published sequence, the original clone (14201) initiated at base 1127 of the published sequence.

15 Figure 7A-7H shows an alignment of the obtained sequences with the published human Hsp 90 nucleotide sequence. Clones 14201.3 and 14201.5 contain part of the 5' untranslated region and therefore the full coding region of the gene has been obtained.

#### Example 2

20 For further method evaluation, a second known gene was selected. A partial sequence from a liver library was found to be related to that of the human cathepsin B gene (accession L16510, HUMCATHB, SEQ ID NO:6). This partial sequence (Incyte clone 87058, SEQ ID NO:7) initiated at base 1066 of the sequence with 25 accession number L16510.

#### 2.1 Primer design

Two primers were designed to perform the method described in the invention:

Primer 1 (XLR) 5' AAG CCA TTG TCA CCC CAG TCA G 3'  
30 (1103-1082)

Primer 2 (XLS) 5' GGT TCA CTG TGG AAT CGA ATC 3'  
(1125-1145)

#### 2.2 Template preparation

A liver cDNA library constructed into the LambdaZAP vector (Stratagene) was converted into a plasmid library following the mass excision protocol. Plasmids of the excised libraries were prepared using the Quiagen Midi plasmid purification kit.

5 2.3 XL-PCR reaction set-up

The extension reactions were prepared following the instructions provided with the GeneAmp XL PCR Kit (Part No. N808-0182) from Perkin Elmer. A two layer system was set up as described below. The lower reagent mix was prepared by pipetting 10 the following components into a 0.2ml MicroAmp reaction tube.

Lower reagent mix preparation:

Water		13.6 $\mu$ l
3.3 x buffer		12.0 $\mu$ l
dATP	(10mM)	2.0 $\mu$ l
15 dCTP	(10mM)	2.0 $\mu$ l
dGTP	(10mM)	2.0 $\mu$ l
dTTP	(10mM)	2.0 $\mu$ l
Primer XLS	(50 $\mu$ M)	1.0 $\mu$ l
Primer XLR	(50 $\mu$ M)	1.0 $\mu$ l
20 Mg (OAc) 2	(25 $\mu$ M)	4.4 $\mu$ l
<hr/>		
Total lower reagent mix		40.0 $\mu$ l

One AmpliWax $\circledR$  gem was added to the tube. This was melted by 25 incubating the reaction tubes at 75°C for 5 minutes. Then the tubes were cooled down to 4°C.

Upper reagent mix preparation:

3.3X buffer	18.0 $\mu$ l
30 rTth DNA Polymerase	2.0 $\mu$ l

---

Total upper enzyme mix 20.0  $\mu$ l

20  $\mu$ l of the enzyme/buffer mix were added to each tube and kept separated from the lower mix by the wax layer.

5 Addition of template:

The template DNA (excised library) was diluted to an appropriate concentration in water and then added to the upper mix. Mixing of the components is not necessary.

Template (6.25ng/ $\mu$ l) 40.0  $\mu$ l

10

---

Final volume 100.0  $\mu$ l

2.4 XL-PCR amplification

For amplification the following protocol was employed:

Step 1 94° for 60 sec (initial denaturation)

15 Step 2 94° for 15 sec

Step 3 65° for 1 min

Step 4 68° for 7 min

Step 5 Repeat step 2-4 for 15 additional times

Step 6 94° for 15 sec

20 Step 7 65° for 1 min

Step 8 68° for 7 min + 15 sec/cycle

Step 9 Repeat step 6-8 for 11 additional times

Step 10 72° for 8 min

Step 11 4° for 0.00 sec (to hold at 4°)

25 2.5 Purification of amplified products

30  $\mu$ l of the amplified products were run on a 0.7% agarose gel for 16 hours. Visible DNA bands were then cut out and purified using the QIAQuick gel purification kit.

2.6 Cloning of amplified products

30 Klenow enzyme (3 units/reaction) and dNTP's (0.2mM final concentration) were added, and the reactions were incubated at room temperature for 30 min followed by incubation at 75°C for 15

min.

The products were then ethanol precipitated and redissolved in 13 µl of ligation buffer containing 1mM ATP. T4-DNA ligase (15 units) and T4 Polynucleotide kinase (5 units) were added, and the 5 reaction was incubated at room temperature for 3 hours.

3 µl of the ligation mixture were transformed into 40 µl of competent E.coli cells. After heatshocking the cells at 42°C for 45 seconds, 80 µl of SOC medium were added; and the cells were allowed to recover at 37°C for 1 hour. The whole transformation 10 mixture then was plated on LB-agar 2x Carb-containing petri dishes.

#### 2.7 Screening of cloned products

The next day 10 colonies were randomly picked and grown overnight in Falcon 2059 tubes (Becton Dickinson, Oxnard, CA 15 93030) containing 3 ml of LB-broth with 2X Carb.

5 µl of the cultures were diluted 1:10 with water and 5 µl of this dilution were transferred into MicroAmp™ PCR tubes (Perkin Elmer, Applied Biosystems, Foster City, CA).

15 µl of a 1.33 x concentrated PCR mix were added to each 20 tube.

The 1.33 x concentrated PCR mix contained the following components:

10 x PCR-buffer	2.0 µl
2mM dNTPs	2.0 µl
25 M13 rev primer (0.01mM)	1.0 µl
Primer 2 (XLR, 0.01mM)	1.0 µl
Taq Polymerase	0.15 µl
water	8.85 µl

---

30 Final Volume 15.0 µl

The PCR cycling conditions were as follows:

Step 1 94°C for 60sec  
Step 2 94°C for 20sec  
Step 3 55°C for 30sec  
Step 4 72°C for 90sec  
5 Step 5 repeat steps 2-4 for an additional 29 times  
Step 6 72°C for 180sec  
Step 7 4°C for ever

Aliquots of the amplified products were run on a 0.8% agarose gel in parallel with the 1kb DNA ladder (Life Technologies, 10 Gaithersburg, MD 20897). Appropriate clones containing different size inserts were selected for sequencing analysis.

## 2.8 Sequencing analysis of cloned products

The DNA of the selected clones was prepared using the Wizard™ Minipreps DNA Purification System (Promega Corporation, 15 Madison, WI) following the instructions of the manufacturer. Sequencing reactions were performed using the PRISM™ Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Part No 401628, Perkin Elmer, Applied Biosystems, Foster City, CA).

## 2.9 Analysis of sequenced products

20 Three clones were selected for sequencing (87058.6, 87058.8, 87058.16). The sequences obtained (SEQ ID NOS:8-10, respectively) were aligned using the DNASIS Multiple sequence alignment program and are shown in Figures 8A through 8F. Clone 87058.6 initiated at base 644 of the published sequence (HUMCATHB, SEQ ID NO:6), 25 clone 87058.8 initiated at base 353 of the published sequence and clone 87058.16 initiated at base 58 of the published sequence, the original clone (87058, SEQ ID NO:7) initiated at base 1058 of the published sequence.

Figures 8A through 8F show an alignment of the obtained 30 sequences with the published human Hsp 90 nucleotide sequence. Clone 87058.16 contains part of the 5'UT and therefore the full coding region of the gene.

### Example 3

In Example 3, a full length cDNA (Seq ID NO 11) of a novel P2U purinergic receptor homolog was obtained by the inventive method and is the subject of U.S. Patent Application 08/459,046 filed June 2, 1995, which is hereby incorporated by reference.

5 Inherit™ and BLAST search and alignment tools were used to relate a partial sequence found in Incyte Clone 179696 from the placental cDNA library to the GenBank sequence of RNU09402, a G-protein coupled surface receptor from rat (Rice WR et al (1995) Am J Respir Cell Molec Biol 12:27-32).

10 The cDNA of Incyte 179696 was extended to full length using a modified XL-PCR (Perkin Elmer) procedure. Primers were designed based on known sequence; one primer was synthesized to initiate extension in the antisense direction (XLR) and the other to extend sequence in the sense direction (XLF). The primers allowed the 15 sequence to be extended "outward" from the known sequence, thus generating amplicons containing new, unknown nucleotide sequence comprising the gene of interest. The primers were designed using Oligo 4.0 (National Biosciences Inc, Plymouth MN) to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to 20 anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

The cDNA library was used as a template, and XLR (bases 278-298) and XLF (bases 587-610) primers were used to extend and 25 amplify the 179696 sequence. By following the instructions for the XL-PCR kit and thoroughly mixing the enzyme, high fidelity amplification is obtained. Beginning with 25 pMol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the MJ PTC200 thermocycler (MJ 30 Research, Watertown MA) and the following parameters:

- Step 1 94° C for 60 sec (initial denaturation)
- Step 2 94° C for 15 sec
- Step 3 65° C for 1 min

Step 4            68° C for 7 min  
Step 5            Repeat step 2-4 for 15 additional cycles  
Step 6            94° C for 15 sec  
Step 7            65° C for 1 min  
5 Step 8           68° C for 7 min + 15 sec/cycle  
Step 9            Repeat step 6-8 for 11 additional cycles  
Step 10           72° C for 8 min  
Step 11           4° C (and holding)

At the end of 28 cycles, 50  $\mu$ l of the reaction mix was  
10 removed; and the remaining reaction mix was run for an additional  
10 cycles as outlined below:

Step 1            94° C for 15 sec  
Step 2            65° C for 1 min  
Step 3            68° C for (10 min + 15 sec)/cycle  
15 Step 4           Repeat step 1-3 for 9 additional cycles  
Step 5            72° C for 10 min

A 5-10  $\mu$ l aliquot of the reaction mixture was analyzed by  
electrophoresis on a low concentration (about 0.6-0.8%) agarose  
mini-gel to determine which reactions were successful in extending  
20 the sequence. Although all extensions potentially contain a full  
length gene, some of the largest products or bands were selected  
and cut out of the gel. Further purification involved using a  
commercial gel extraction method such as QIAQuick™ (QIAGEN Inc,  
Chatsworth CA). After recovery of the DNA, Klenow enzyme was used  
25 to trim single-stranded, nucleotide overhangs creating blunt ends  
which facilitated religation and cloning.

After ethanol precipitation, the products were redissolved in  
13  $\mu$ l of ligation buffer. Then, 1 $\mu$ l T4-DNA ligase (15 units) and  
1 $\mu$ l T4 polynucleotide kinase were added, and the mixture was  
30 incubated at room temperature for 2-3 hours or overnight at 16° C.  
Competent *E. coli* cells (in 40  $\mu$ l of appropriate media) were  
transformed with 3  $\mu$ l of ligation mixture and cultured in 80  $\mu$ l of  
SOC medium (Sambrook J et al, supra). After incubation for one

hour at 37° C, the whole transformation mixture was plated on Luria Broth (LB)-agar (Sambrook J et al, *supra*) containing carbenicillin at 25 mg/L. The following day, 12 colonies were randomly picked from each plate and cultured in 150 µl of liquid

5 LB/carbenicillin medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 µl of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 µl of each sample was transferred into a PCR

10 array.

For PCR amplification, 15 µl of concentrated PCR reaction mix (1.33X) containing 0.75 units of Taq polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was

15 performed using the following conditions:

Step 1            94° C for 60 sec  
Step 2            94° C for 20 sec  
Step 3            55° C for 30 sec  
Step 4            72° C for 90 sec  
20 Step 5          Repeat steps 2-4 for an additional 29 cycles  
Step 6            72° C for 180 sec  
Step 7            4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR

25 products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid and sequenced.

Example 4

In this example, the inventive method was used to obtain a

30 novel full length cDNA from the partial sequence found in Incyte clone 08118 which was found to be somewhat homologous to the GenBank sequence of C5a anaphylatoxin receptor, a G-protein coupled surface receptor from dog (Perret J et al (1995) Biochem

J 288:911-17). Based on the partial cDNA sequence, primers (XLR = GAAAGACAGCCACCACCACG and XLF = AGAAAGCAAGGCAGTCCATTCAAGG ) were designed. Essentially the same method outlined in Example 3 above was used to extend the partial sequence of 8118 to obtain 5 the full length sequence (Seq ID NO:12) of a novel C5a-like receptor homolog which is the subject of a U.S. Patent Application 08/462,355 filed June 5, 1995, and whose disclosure is incorporated by reference.

While the present invention has been described with reference 10 to specific enzymes and sequences, particularly PCR enzyme, and formulations containing such, those skilled in the art understand that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to 15 adapt a particular situation, material, enzyme, process, process step or steps and still carry out the objective, spirit and scope of the invention. All such modifications are intended to be within the scope of the claims appended hereto.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: INCYTE PHARMACEUTICALS, INC.

(ii) TITLE OF INVENTION: IMPROVED METHOD FOR OBTAINING  
FULL LENGTH cDNA SEQUENCES

(iii) NUMBER OF SEQUENCES: 12

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: INCYTE PHARMACEUTICALS, INC.  
(B) STREET: 3330 Hillview Avenue  
(C) CITY: Palo Alto  
(D) STATE: CA  
(E) COUNTRY: USA  
(F) ZIP: 94304

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To Be Assigned  
(B) FILING DATE: Filed Herewith

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/487,112  
(B) FILING DATE: 7-JUN-1995

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/462,355  
(B) FILING DATE: 5-JUN-1995

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/459,046  
(B) FILING DATE: 2-JUN-1995

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/566,334  
(B) FILING DATE: 1-DEC-1995

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 60/006,809  
(B) FILING DATE: 15-NOV-1995

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Luther, Barbara J.  
(B) REGISTRATION NUMBER: 33954  
(C) REFERENCE/DOCKET NUMBER: HP-001-1 PCT

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415-855-0555

(B) TELEFAX: 415-852-0195

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2543 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank HUMHSP90
- (B) CLONE: Accession No. M16660

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTCCGGCGCA	GTGTTGGAC	TGTCTGGTA	TCGGAAAGCA	AGCCTACGTT	GCTCACTATT	60
ACGTATAATC	CTTTTCTTTT	CAAGATGCCT	GAGGAAGTGC	ACCATGGAGA	GGAGGAGGTG	120
GAGACTTTG	CCTTCAGGC	AGAAATTGCC	CAACTCATGT	CCCTCATCAT	CAATACCTTC	180
TATTCCAACA	AGGAGATTTT	CCTTCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCCTGGAC	240
AAGATTCGCT	ATGAGAGCCT	GACAGACCCCT	TCGAAGTTGG	ACAGTGGTAA	AGAGCTGAAA	300
ATTGACATCA	TCCCCAACCC	TCAGGAACGT	ACCCCTGACTT	TGGTAGACAC	AGGCATTGGC	360
ATGACCAAAG	CTGATCTCAT	AAATAATTG	GGAACCATTG	CCAAGTCTGG	TACTAAAGCA	420
TTCATGGAGG	CTCTTCAGGC	TGGTGCAGAC	ATCTCCATGA	TTGGGCAGTT	TGGTGTGGC	480
TTTTATTCTG	CCTACTTGGT	GGCAGAGAAA	GTGGTTGTGA	TCAGAAAGCA	CAACGATGAT	540
GAACAGTATG	CTTGGGAGTC	TTCTGCTGGA	GGTTCCCTCA	CTGTGCGTGC	TGACCATGGT	600
GAGCCCATTG	GCATGGGTAC	CAAAGTGATC	CTCCATCTTA	AAGAAGATCA	GACAGAGTAC	660
CTAGAAAGAGA	GGCGGGTCAA	AGAAGTAGTG	AAGAAGCATT	CTCAGTTCAT	AGGCTATCCC	720
ATCACCCCTT	ATTTGGAGAA	GGAACGAGAG	AAGGAAATT	GTGATGATGA	GGCAGAGGAA	780
GAGAAAGGTG	AGAAAAGAAGA	GGAAGATAAA	GATGATGAAG	AAAAGCCCAA	GATCGAAGAT	840
GTGGGTTTCAG	ATGAGGAGGA	TGACAGCGGT	AAGGATAAGA	AGAAGAAAAC	TAAGAAGATC	900
AAAGAGAAAT	ACATTGATCA	GGAAGAACTA	AACAAGACCA	AGCCTATTTG	GACCAGAAC	960
CCTGATGACA	TCACCCAAGA	GGAGTATGGA	GAATTCTACA	AGAGCCTCAC	TAATGACTGG	1020
GAAGACCACT	TGGCAGTCAA	GCACCTTTCT	GTAGAAGGTC	AGTTGGAATT	CAGGGCATTG	1080
CTATTTATTC	CTCGTCGGGC	TCCCTTTGAC	CTTTTGAGA	ACAAGAAGAA	AAAGAACAAAC	1140
ATCAAACCTCT	ATGTCCGCCG	TGTGTTCATC	ATGGACAGCT	GTGATGAGTT	GATACCAGAG	1200

TATCTCAATT TTATCCGTGG TGTGGTTGAC TCTGAGGATC TGCCCCTGAA CATCTCCCGA	1260
GAAATGCTCC AGCAGAGCAA AATCTTGAAA GTCATTGCA AAAACATTGT TAAGAAGTGC	1320
CTTGAGCTCT TCTCTGAGCT GGCAGAAGAC AAGGAGAATT ACAAGAAATT CTATGAGGCA	1380
TTCTCTAAAA ATCTCAAGCT TGGAATCCAC GAAGACTCCA CTAACCGCCG CCGCCTGTCT	1440
GAGCTGCTGC GCTATCATACT CTCAGCTCT GGAGATGAGA TGACATCTCT GTCAGAGTAT	1500
GTTTCTCGCA TGAAGGAGAC ACAGAAGTCC ATCTATTACA TCACTGGTGA GAGCAAAGAG	1560
CAGGTGGCCA ACTCAGCTTT TGTGGAGCGA GTGCGGAAAC GGGGCTTCGA GGTGGTATAT	1620
ATGACCGAGC CCATTGACGA GTACTGTGTG CAGCAGCTCA AGGAATTGTA TGGGAAGAGC	1680
CTGGTCTCAG TTACCAAGGA GGGTCTGGAG CTGCCTGAGG ATGAGGAGGA GAAGAAGAAG	1740
ATGGAAGAGA GCAAGGCAAA GTTGAGAAC CTCTGCAAGC TCATGAAAGA AATCTTAGAT	1800
AAGAAGGTTG AGAAGGTGAC AATCTCAAAT AGACTTGTGT CTTCACCTTG CTGCATTGTG	1860
ACCAGCACCT ACGGCTGGAC AGCCAATATG GAGCGGATCA TGAAAGCCCA GGCACCTCGG	1920
GACAACCTCCA CCATGGGCTA TATGATGGCC AAAAAGCACC TGGAGATCAA CCCTGACCAC	1980
CCCATTGTGG AGACGCTGCG GCAGAAGGCT GAGGCCGACA AGAATGATAA GGCAGTTAAG	2040
GACCTGGTGG TGCTGCTGTT TGAAACCGCC CTGCTATCTT CTGGCTTTTC CCTTGAGGAT	2100
CCCCAGACCC ACTCCAACCG CATCTATCGC ATGATCAAGC TAGGTCTAGG TATTGATGAA	2160
GATGAAGTGG CAGCAGAGGA ACCCAATGCT GCAGTTCTG ATGAGATCCC CCCTCTCGAG	2220
GGCGATGAGG ATGCGTCTCG CATGGAAGAA GTCGATTAGG TTAGGAGTTC ATAGTTGGAA	2280
AACTTGTGCC CTTGTATAGT GTCCCCATGG GCTCCCACTG CAGCCTCGAG TGCCCCCTGTC	2340
CCACCTGGCT CCCCCCTGCTG GTGTCTAGTG TTTTTTCCC TCTCCTGTCC TTGTGTTGAA	2400
GGCAGTAAAC TAAGGGTGTC AAGCCCCATT CCCTCTCTAC TCTTGACAGC AGGATTGGAT	2460
GTTGTGTATT GTGGTTTATT TTATTTCTT CATTGTTTC TGAAATTAAA GTATGCAAAA	2520
TAAAGAATAT GCCGTTTTTA TAC	2543

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 261 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:  
 (A) LIBRARY: THP-1  
 (B) CLONE: 14201

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AAGAAAAAAGA ACAACATCAA ACTCTATGTC CGCCGTGTGT TCATCATGGC AGCTGTGATG	60
AGTTGATACC AGAGTATCTC AATTTTATCC GTGGTGTGGT TGACTTGAGG TCTGCCCTG	120
AACATCTCCC GGAAATGCTC CAGCAGAGCA AAATCTTGAA AGGCATTGCG AAAAACATTG	180
TTAAGAGTGC CTTAGCTCTT CTCTAGCTGG CAGAAGCAAG GGGATTTCAA GAAATTCTTT	240
TGGGGGGATT TCTTAAAAAT T	261

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 478 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:  
 (A) LIBRARY: THP-1  
 (B) CLONE: 14201.3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCTGGGTATC GGAAAGCAAG CCTACGTTGC TCACTATTAC GTATAATCCT TTTCTTCAAG	60
ATGCCTGAGG AAGTGCACCA TGGAGAGGAG GAGGTGGAGA CTTTGCCCTT TCAGGCAGAA	120
ATTGCCAAC TCATGTCCCT CATCATCAAT ACCTCCTATT CCAACAAGGA GATTTCCCTCG	180
GGAGTTGATC TCTAATGCTT CTGATGCCTC GGACAAGATT CGCTATGAAG CCTGACAGAC	240
CCTTCGAAGT GGTCAGCGGC AAGAGCTGAA AATTGACATC ATCCCCAACC CTCAGGAACG	300
TCCCTGTACT TTGGGTAGAC ACAGGCATTG GCATAAACAA AGCTGACCTC ATATTATTG	360
GGGAACCATT GCCAAGTCTT GTCTAAAAGC ATTCAATGGAG GCTCTCAGGT TGGCGCAGAC	420
ATCTCCAGAT TGGCAGGTGG GTGTTGGCTT TATTCTGCCC ACTTGGTGGC AGAGAAAT	478

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 508 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: THP-1
- (B) CLONE: 14201.5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTGGGGACTG TCTGGGTATC GGAAAGCAAG CCTACGTTGC TCACTATTAC GTATAATCCT	60
TTCTTTTCA AGATGCCCTGA GGAAGTGCAC CATGGAGAGG AGGAGGTGGA GACTTTTGCC	120
TTTCAGGCAG AAATTGCCCA ACTCATGTCC CTCATCATCA ATACCTCCTA TTCCAACAAG	180
GAGATTTTCC TTCGGGAGTT GATCTCTAAT GCTTCTGATG CCTTGGACAA GATTCGCTAT	240
GAGAGCCTGA CAGACCCCTTC GAAGTTGGAC AGTGGTAAAG AGCTGAAAAT TGACATCATC	300
CCCAACCCCTC AGGAACGTAC CCTGACTTTG GGTAGACACA GGCATCGGCA TGACAAAAG	360
CTGATCTCAT AATAATTGGG AACCATTGCA AGTCTGGTAC TAAAGCATTG ATGGAGGCTC	420
TTCAGGCTGG TGCAGACATC TCCATGATTG GGCAGCTTGG GTGTTGCTTT ATTCTGCCTC	480
CTTGGTGGCA GAGAAAGTGT TGTGATCA	508

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 547 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: THP-1
- (B) CLONE: 14201.13

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTGAGAGTAT GTCGAGTTAC TGTGGAGGTT CCTTCACTGC GTGCTGACAT GGTGAGCCCA	60
TGGGAGCGGT ACCAAGTGAT CCTCCATCTC AAAGAAGATC AGACAGAGTA CCTAGAGAGA	120
GGCGGATCAA AGAGTAGTGA TGAGCATCCT CAGATCATAG GCTATCCCAT CACCCCTTTT	180
TGGAGAAGGA CGAGAGAAGG AATTAGGATG ATGAGGCAGA GGAAGAGAAAT GGTGAGAAATG	240
AAGAGGAGTA ACGATGATGA AGAAACCCCA AGATCGATGA TGTGGTTCAAG ATGAGGGGAT	300
GACAGCGGTA GATAAGAAGA AGAAACTAGA ATCATCGGAT CATGACAGAGGA AGAACTAACAA	360
GATCATCTTT CGGCCAGAAT CCCTGATGTC ATCACCCAAG AGGGTATGGA GATTCTACA	420
TGCAGCTCAC TTTACTGGGC AAGACACTTG GCAGCAACAC TTTCTGTAG AAGGCCATTG	480

CATCACGCAT TGCTATTCTT CCCTCGCCGT CTCCCTTGAC CTGGTCTGGC ATCATGGTGT 540

CTTGATC 547

## (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1996 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank HUMCATHB
- (B) CLONE: Accession No. L16510

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TCCGGCAACG CCAACCGCTC CGCTGCGCGC AGGCTGGGCT GCAGGCTCTC GGCTGCAGCG	60
CTGGGCTGGT GTGCAGTGGT GCGACCACGG CTCACGGCAG CCTCAGCCAC CCAGATGTAA	120
GCGATCTGGT TCCCACCTCA GCCTCCCGAG TAGTGGATCT AGGATCCGGC TTCCAACATG	180
TGGCAGCTCT GGGCCTCCCT CTGCTGCCTG CTGGTGTGG CCAATGCCCG GAGCAGGCC	240
TCTTTCCATC CCCTGTCGGA TGAGCTGGTC AACTATGTCA ACAAACGGAA TACCACGTGG	300
CAGGCCGGC ACAACTTCTA CAACGTGGAC ATGAGCTACT TGAAGAGGCT ATGTGGTACC	360
TTCCCTGGGTG GGCCAAGCC ACCCCAGAGA GTTATGTTA CCGAGGACCT GAAGCTGCCT	420
GCAAGCTTCG ATGCACGGGA ACAATGGCCA CAGTGTCCC CCATCAAAGA GATCAGAGAC	480
CAGGGCTCCT GTGGCTCCTG CTGGGCCTTC GGGGCTGTGG AAGCCATCTC TGACCGGATC	540
TGCATCCACA CCAATGCGCA CGTCAGCGTG GAGGTGTGG CGGAGGACCT GCTCACATGC	600
TGTGGCAGCA TGTGTGGGA CGGCTGTAAT GGTGGCTATC CTGCTGAAGC TTGGAACCTC	660
TGGACAAGAA AAGGCCTGGT TTCTGGTGGC CTCTATGAAT CCCATGTAGG GTGCAGACCG	720
TACTCCATCC CTCCCTGTGA GCACCACGTC AACGGCTCCC GGCCCCCATG CACGGGGAG	780
GGAGATAACC CCAAGTGTAG CAAGATCTGT GAGCCTGGCT ACAGCCCGAC CTACAAACAG	840
GACAAGCACT ACGGATACAA TTCCTACAGC GTCTCCAATA GCGAGAAGGA CATCATGCC	900
GAGATCTACA AAAACGGCCC CGTGGAGGGA GCTTTCTCTG TGTATTGGC CTTCCCTGCTC	960
TACAAGTCAG GAGTGTACCA ACACGTCACC GGAGAGATGA TGGGTGGCCA TGCCATCCGC	1020
ATCCTGGGCT GGGGAGTGGA GAATGGCACA CCCTACTGGC TGGTTGCCAA CTCCTGGAAC	1080
ACTGACTGGG GTGACAATGG CTTCTTTAAA ATACTCAGAG GACAGGATCA CTGTGGAATC	1140

GAATCAGAAG TGGTGGCTGG AATTCCACGC ACCGATCAGT ACTGGGAAAA GATCTAATCT	1200
GCCGTGGGCC TGTCTGCCA GTCCTGGGG CGAGATCGGG GTAGAAATGC ATTTTATTCT	1260
TTAAGTTCAC GTAAGATACA AGTTTCAGGC AGGGTCTGAA GGACTGGATT GGCCAAACAT	1320
CAGACCTGTC TTCCAAGGAG ACCAAGTCCT GGCTACATCC CAGCCTGTGG TTACAGTGCA	1380
GACAGGCCAT GTGAGCCACC GCTGCCAGCA CAGAGCGTCC TTCCCCCTGT AGACTAGTGC	1440
CGTGGGAGTA CCTGCTGCCA AGCTGCTGTG GCCCCCTCCG TGATCCATCC ATCTCCAGGG	1500
AGCAAGACAG AGACGCAGGA TGGAAAGCGG AGTTCTAAC AGGATGAAAG TTCCCCCATC	1560
AGTTCCCCCA GTACCTCCAA GCAAGTAGCT TTCCACATTT GTCACAGAAA TCAGAGGAGA	1620
GATGGTGTG AGGACCCCTT GGAGAACGCC AGTCTCCAGG TCCCCCTGCA TCTATCGAGT	1680
TTGCAATGTC ACAACCTCTC TGATCTTGTG CTCAGCATGA TTCTTTAATA GAAGTTTAT	1740
TTTCGTGCA CTCTGCTAAT CATGTGGGTG AGCCAGTGGG ACAGCGGGAG CCTGTGCTGG	1800
TTTGCAGATT GCCTCCTAAT GACGCGGCTC AAAAGGAAAC CAAGTGGTCA GGAGTTGTTT	1860
CTGACCCACT GATCTCTACT ACCACAAGGA AAATAGTTA GGAGAAACCA GCTTTTACTG	1920
TTTTGAAAAA ATTACAGCTT CACCCGTCA AGTTAACAAAG GAATGCCCTGT GCCAATAAAA	1980
GGTTTCTCCA ACTTGAA	1996

## (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 294 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: LIVER
- (B) CLONE: 87058

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGGCACGAGC CAACTCCTGG AACACTGACT GGGGTGACAA TGGCTTCTTT AAAATACTCA	60
GAGGACAGGT TCACTGTGGA ATCGAATCAG AAGTGGTGGC TGGATTCCA CGCACCGTTC	120
AGTACTGGGA AAAGTCTAAT CTGCCGTGGG CCTTCGTGCC AGTCCTGGGG GCGAGATGGG	180
GGTAGAAATG CATTCTATTC TTTAAGTTCA CGTAAGATAC AAGTTTCAGA CAGGGGTCTA	240
AGGCCTGGTT GCCAAAATCA GACCTGTTT TCAAGGGGCC CAAGTCCTGG GTTC	294

## (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 552 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:  
 (A) LIBRARY: Liver  
 (B) CLONE: 87058.6

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GTTGAAGCTTG	GAACCTTCTGG	ACAAGAAAAG	GCCTGGTTTC	TGGTGGCCTC	TATGAATCCC	60
ATGTAGGGTG	CAGACCGTAC	TCCATCCCTC	CCTGTGAGCA	CCACGTCAAC	GGCTCCCGGC	120
CCCCATGCAC	GGGGGAGGGA	GATACCCCCA	AGTGTAGCAA	GATCTGTGAG	CCTGGCTACA	180
GCCCCGACCTA	CAAACAGGAC	AAGCACTACG	GATACAATTG	CTACAGCGTC	TCCAATAGCG	240
AGAAGGACAT	CATGGCCGAG	ATCTACAAAA	ACGGCCCCGT	GGAGGGAGCT	TTCTCTGTGT	300
ATTCGGACTT	CCTGCTCTAC	AAGTCAGGAG	TGTACCAACA	CGTCACCGGA	GAGATGATGG	360
GTGGCCATGC	CATCCGCATC	CTGGGCTGGG	GAGTGGAGAA	TGGCACAAACC	TACTGGCTGG	420
TTGGCAACTC	CTGGAACACT	GACTGGGTG	ACAATGGTTT	CACTGTGGAA	TCGAATCAGA	480
AGTGGTGGTG	GAATTCCACG	CACGATCAAG	TGCTGGAAA	AGATCTTAAT	CTGCCGGGGC	540
TGTCGGCCAG	TC					552

## (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 559 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:  
 (A) LIBRARY: Liver  
 (B) CLONE: 87058.8

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAGGTACCTT	CCTGGGTGGG	CCCAAGCCAC	CCCAGAGAGT	TATGTTTACC	GAGGACCTGA	60
AGCTGCCTGC	AAGCTTCGAT	GCACGGGAAC	AATGCCACA	GTGTCCCACC	ATCAAAGAGA	120
TCAGAGACCA	GGGTCCGTG	GCTCCTGCTG	GGCCTTCGGG	GCTGTGGAAG	CCATCTCTGA	180

CCGGATCTGA TCCACACCAA TGCGCACGTC AGCGTGGAGG TGTGGCGGA GGACTGCTCA	240
CATGCTGTGG CAGATGTGTG GGGACGGCTG TAATGGTGGC TATCCTGCTG AAGCTTGGAC	300
TTCTGGACAA GAAAAGGCC C TGGTTTCTGG TGGCCTCTAT GATCCCATGT AGGGTGTAGA	360
CCGTACTCCA TCCCTCCCTG TGAAGCACCA CGTCAACGGT TCCCGGGCCC CATGCACGGG	420
GAGGGAGATA CCCCCAAGTG TAACAAGATC TGTGAGCCTG GGTACAGTCC CGACCACAAA	480
CAGGAAAAGC ACTACGGATA CAATTCCCTCA GGTCTCCAAT AGTGAGAAGG GACATCATGC	540
CGAGATCTAC AATAACGGC	559

## (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 622 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: Liver
- (B) CLONE: 87058.16

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGTTGAGAT TCGGACAGTC CGAAAACGTC CGGCAAGTCA CCCGCTCCGC TGGCGCAGGC	60
TGGGTGCAGG CTCTCGGTGC AGGCTGGGTG GATCTAGGAT CCGGCTTCCA ACATGTGGCA	120
GTTCTGGGCC TCCCTCTGTG CCTGCTGGTG TTGGACAATG CCCGGAGGAG GCCTCTTTCC	180
ATCCCCCTGTC GGATGAGCTG GTCACTATGT CAACAAACGG AATACCACGT GGAGGCCCC	240
AACAACTTCT ACAACGTGGA CATGAGCTAC TTGAGAGGTA TGTGGTACCT TCCTGGGTGG	300
GCCCAAGCCA CCCCAGAGAG TTTGTTTACC GAGGACCTGA GCTGCCTGCA AGCTTCGAAG	360
GACGGGAACA ATGGCCACAG TGTCCCACCA TCAAAGAGAT CAGAGACAGG GCTCCTGTGG	420
TCCTGCTGGG CCTCCGGGGC TGTGGAAGCA TCTCTGACCG GATCTGCATC CACACCAATG	480
GCACGTCAGC GTGGTGGTGT CGGGGAGGAC CTGATCACCT TTGTGGTAGC ATGTGTGGGG	540
GACGGCTGTA ATGGTGGTTA TCCTGTGAAG CTGGCCTTC TAGAAAGAAA AGGCTGTTT	600
GGTGGCCTTA TGACTCCCCAT GT	622

## (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 984 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
 

- (A) LIBRARY: Placenta
- (B) CLONE: 179696

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGGAATGGG ACAATGGCAC AGACCAGGCT CTGGGCTTGC CACCCACCAC CTGTGTCTAC	60
CGCGAGAACT TCAAGCAACT GCTGCTCCCA CCTGTGTATT CGGCAGGTGCT GGCGCCTGCC	120
CTCCCCTGTA ACATCTGTGT CATTACCCAG ATCTGCACGT CCCGCCGGGC CCTGACCCGC	180
ACGGCCGTGT ACACCCCTAAA CCTTGCTCTG CCTGACCTGC TATATGCCTG CTCCCTGCC	240
CTGCTCATCT ACAACTATGC CCAAGGTGAT CACTGGCCCT TTGGCGACTT CGCCTGCC	300
CTGGTCCGCT TCCTCTTCTA TGCCAACCTG CACGGGAGGA TCCTCTTCCT CACCTGCATC	360
AGCTTCCAGC GCTACCTGGG CATCTGCCAC CCGCTGGCCC CCTGGCACAA ACGTGGGGC	420
CGCCGGGCTG CCTGGCTAGT GTGTGTAGCC GTGTGGCTGG CCGTGACAAC CCAGTGCCTG	480
CCCACAGCCA TCTTCGCTGC CACAGGCATC CAGCGTAACC GCACTGTCTG TTATGACCTC	540
AGCCCGCCTG CCCTGGCCAC CCACTATATG CCCTATGGGA TGGCTCTCAC TGTCA	600
CGGC	CG
TTCCCTGCTGC CCTTTGCTGC CCTGCTGGCC TGCTACTGTC TCCTGGCCTG CCGCCTGTGC	660
CGCCAGGATG GCCCGGCAGA GCCTGTGGCC CAGGAGCGGC GTGGCAAGGC GGCCCGCATG	720
GCCGTGGTGG TGGCTGCTGT CTTTGGCATC AGCTTCC	780
GCCTACCTGG CAGTGC	780
GCCTACCTGG CAGTGC	840
GCCTACCTGG CAGTGC	900
GCCTACCTGG CAGTGC	960
GCCTACCTGG CAGTGC	984

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
 

- (A) LENGTH: 1446 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Mast Cell  
 (B) CLONE: 8118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATGGCGTCTT TCTCTGCTGA GACCAATTCA ACTGACCTAC TCTCACAGCC ATGGAATGAG	60
CCCCCAGTAA TTCTCTCCAT GGTCAATTCTC AGCCTTACTT TTTTACTGGG ATTGCCAGGC	120
AATGGGCTGG TGCTGTGGGT GGCTGGCCTG AAGATGCAGC GGACAGTGAA CACAATTGG	180
TTCCCTCCACC TCACCTTGGC GGACCTCCTC TGCTGCCTCT CCTTGGCCTT CTCGCTGGCT	240
CACTTGGCTC TCCAGGGACA GTGGCCCTAC GGCAGGTTCC TATGCAAGCT CATCCCCCTCC	300
ATCATTGTCC TCAACATGTT TGGCAGTGTC TTCTGCTTA CTGCCATTAG CCTGGATCGC	360
TGTCTTGTGG TATTCAAGCC AATCTGGTGT CAGAATCATC GCAATGTAGG GATGGCCTGC	420
TCTATCTGTG GATGTATCTG GGTGGTGGCT TTTGTGTTGT GCATTCCGT GTTCGTGTAC	480
CGGGAAATCT TCACTACAGA CAACCATAAT AGATGTGGCT ACAAAATTGG TCTCTCCAGC	540
TCATTAGATT ATCCAGACTT TTATGGGGAT CCACTAGAAA ACAGGTCTCT TGAAAACATT	600
GTTCAGCCGC CTGGAGAAAT GAATGATAGG TTAGATCCTT CCTCTTTCCA AACAAATGAT	660
CATCCTTGGA CAGTCCCCAC TGTCTTCCAA CCTCAAACAT TTCAAAGACC TTCTGCAGAT	720
TCACTCCCTA GGGGTTCTGC TAGGTTAACCA AGTCAAAATC TGTATTCTAA TGTATTTAAA	780
CCTGCTGATG TGGTCTCACC TAAAATCCCC AGTGGGTTTC CTATTGAAGA TCACGAAACC	840
AGCCCACCTGG ATAACCTCTGA TGCTTTCTC TCTACTCATT TAAAGCTGTT CCCTAGCGCT	900
TCTAGCAATT CCTTCTACGA GTCTGAGCTA CCACAAGGTT TCCAGGATTA TTACAATTAA	960
GGCCAATTCA CAGATGACGA TCAAGTGCCA ACACCCCTCG TGGCAATAAC GATCACTAGG	1020
CTAGTGGTGG GTTTCTGCT GCCCTCTGTT ATCATGATAG CCTGTTACAG CTTCATTGTC	1080
TTCCGAATGC AAAGGGGCCG CTTCGCCAAG TCTCAGAGCA AAACCTTTCG AGTGGCCGTG	1140
GTGGTGGTGG CTGTCCTTCT TGTCTGCTGG ACTCCATACC ACATTTGGGG AGTCCTGTCA	1200
TTGCTTACTG ACCCAGAAAC TCCCTTGGGG AAAACTCTGA TGTCTGGGA TCATGTATGC	1260
ATTGCTCTAG CATCTGCCAA TAGTTGCTTT AATCCCTTCC TTTATGCCCT CTTGGGGAAA	1320
GATTTTAGGA AGAAAGCAAG GCAGTCCATT CAGGGAATTC TGGAGGCAGC CTTCACTGAG	1380
GAGCTCACAC GTTCCACCCA CTGTCCCTCA AACAAATGTCA TTTCAAGAAAG AAATAGTACA	1440
ACTGTG	1446

## CLAIMS

1. A method of extending the sequence of a partial complementary DNA (cDNA) using polymerase chain reaction (PCR), comprising the steps of:

5 a) combining a first and second PCR primer with nucleic acid from a cDNA library expected to contain said partial cDNA, or a genomic library, under conditions suitable for synthesis of nucleic acid PCR products from the first and second primers, wherein said first and second primers are capable of annealing to

10 opposite strands of the partial cDNA or genomic DNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA polymerase in an antisense direction and the second primer is capable of being extended in a sense direction.

15 b) purifying the PCR products, and

c) identifying extended nucleotide sequences derived from said partial cDNA or said genomic DNA.

2. The method of Claim 1 wherein identifying extended sequences comprises nucleic acid sequencing.

20 3. The method of Claim 2 further comprising extending the nucleotide sequences of step 6c by repeating steps 6a through 6c on the nucleotide sequences identified in step 6c.

4. A method of extending the nucleotide sequence of a partial complementary DNA (cDNA) using polymerase chain reaction

25 (PCR), comprising the steps of:

a) combining a first and second PCR primer with nucleic acid from a cDNA library expected to contain said partial cDNA, or a genomic library, under conditions suitable for synthesis of nucleic acid PCR products from the first and second primers,

30 wherein said first and second primers are capable of annealing to opposite strands of the partial cDNA or genomic DNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA polymerase in an

antisense direction and the second primer is capable of being extended in a sense direction.

- b) purifying the PCR products,
- c) ligating the purified PCR products under conditions 5 suitable for the formation of circular closed nucleic acid,
- d) transforming a host cell with the circular closed nucleic acid and culturing the transformed host cell under conditions suitable for growth,
- e) recovering said circular closed nucleic acid from the 10 cultured, transformed host cell,
- f) identifying extended nucleotide sequences derived from said partial cDNA or said genomic DNA.

5. The method of Claim 4 wherein identifying extended sequences comprises nucleic acid sequencing.

15 6. The method of Claim 4 wherein culturing the transformed host cell under conditions suitable for growth comprises culturing in the presence of selective antibiotic conditions.

7. The method of Claim 4 wherein said host cell is E.coli.

8. The method of Claim 4 wherein after step 4b and prior to step 20 4c, the purified PCR products are treated under conditions suitable for converting nucleic acid overhangs to blunt ends.

1/20






FIGURE 1


2/20

**FIGURE 2**


3/20

**FIGURE 3**

4/20

**FIGURE 4**

5/20

**FIGURE 5**

6/20




FIGURE 6

7/20

	10	20	30	40	50	
Hsp 90	1 CTCCGGCGCA	GTGTTGGGAC	TGTCTGGGT	TCGGAAAGCA	AGCCTACGTT	50
14201	1 -----	-----	-----	-----	-----	50
14201.3	1 -----	-----	-----	-----	-----	50
14201.5	1 -----	-----	-----	-----	-----	50
14201.13	1 -----	-----	-----	-----	-----	50
	60	70	80	90	100	
Hsp 90	51 GCTCACTATT	ACGTATAATC	CTTTTCTTTT	CAAGATGCCT	GAGGAAGTGC	100
14201	51 -----	-----	-----	-----	-----	100
14201.3	51 GCTCACTATT	ACGTATAATC	CTTTTCTNTN	CAAGATGCCT	GAGGAAGTGC	100
14201.5	51 GCTCACTATT	ACGTATAATC	CTTTTCTTTT	CAAGATGCCT	GAGGAAGTGC	100
14201.13	51 -----	-----	-----	-----	-----	100
	110	120	130	140	150	
Hsp 90	101 ACCATGGAGA	GGAGGGAGGTG	GAGACTTTTG	CCTTTCAGGC	AGAAATTGCC	150
14201	101 -----	-----	-----	-----	-----	150
14201.3	101 ACCATGGAGA	GGAGGGAGGTG	GAGACTTTTG	CCTTTCAGGC	AGAAATTGCC	150
14201.5	101 ACCATGGAGA	GGAGGGAGGTG	GAGACTTTTG	CCTTTCAGGC	AGAAATTGCC	150
14201.13	101 -----	-----	-----	-----	-----	150
	160	170	180	190	200	
Hsp 90	151 CAACTCATGT	CCCTCATCAT	CAATACCTTC	TATTCCAACA	AGGAGATTTT	200
14201	151 -----	-----	-----	-----	-----	200
14201.3	151 CAACTCATGT	CCCTCATCAT	CAATACCTCC	TATTCCAACA	AGGAGATTNT	200
14201.5	151 CAACTCATGT	CCCTCATCAT	CAATACCTCC	TATTCCAACA	AGGAGATTT	200
14201.13	151 -----	-----	-----	-----	-----	200
	210	220	230	240	250	
Hsp 90	201 CCTTCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCTTGGAC	AAGATTGCT	250
14201	201 -----	-----	-----	-----	-----	250
14201.3	201 CCTNCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCTTGGAC	AAGATTGCT	250
14201.5	201 CCTTCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCTTGGAC	AAGATTGCT	250
14201.13	201 -----	-----	-----	-----	-----	250
	260	270	280	290	300	
Hsp 90	251 ATGAGAGCCT	GACAGACCCCT	TCGAAGTTGG	ACAGTGGTAA	AGAGCTGAAA	300
14201	251 -----	-----	-----	-----	-----	300
14201.3	251 ATGANAGCCT	GACAGACCCCT	TCGAAGTNGG	TCAGCGGCAA	NGAGCTGAAA	300
14201.5	251 ATGAGAGCCT	GACAGACCCCT	TCGAAGTTGG	ACAGTGGTAA	AGAGCTGAAA	300
14201.13	251 -----	-----	-----	-----	-----	300

FIGURE 7A

8/20

		310	320	330	340	350	
Hsp 90	301	ATTGACATCA	TCCCCAACCC	TCAGGAACGT	ACCCTGACTT	TGGTAGACAC	350
14201	301	-----	-----	-----	-----	-----	350
14201.3	301	ATTGACATCA	TCCCCAACCC	TCAGGAACGT	NCCCTGACTT	TGGTAGACAC	350
14201.5	301	ATTGACATCA	TCCCCAACCC	TCAGGAACGT	ACCCTGACTT	TGGTAGACAC	350
14201.13	301	-----	-----	-----	-----	-----	350
		360	370	380	390	400	
Hsp 90	351	AGGCATTGGC	ATGACCAAAG	CTGATCTCAT	AAaTAATTtG	GGAACCATTG	400
14201	351	-----	-----	-----	-----	-----	400
14201.3	351	AGGCATTGGC	ATGAAacAAG	CTGAcCTCAT	NAntTATTcG	GGgAaCcATt	400
14201.5	351	AGGCATCGGC	ATGACCAAAG	CTGATCTCAT	AAntTAATTnG	GGAACCATTG	400
14201.13	351	-----	-----	-----	-----	-----	400
		410	420	430	440	450	
Hsp 90	401	CCAAGTCTGG	TACTAAAGCA	TTCATGGAGG	CTCTTCAGGC	TGGTGCAGAC	450
14201	401	-----	-----	-----	-----	-----	450
14201.3	401	CCAAGTCTTG	TNCTAAAGCA	TTCATGGAGG	CTCTNCAGGN	TGGcGCAGAC	450
14201.5	401	NCAAGTCTGG	TACTAAAGCA	TTCATGGAGG	CTCTTCAGGC	TGGTGCAGAC	450
14201.13	401	-----	-----	-----	-----	-----	450
		460	470	480	490	500	
Hsp 90	451	ATCTCCATGA	TTGGGCAGTT	tGGTGTGTC	TttTATTCTG	CCTACTTGGT	500
14201	451	-----	-----	-----	-----	-----	500
14201.3	451	ATCTCCANGA	TTNGGCAGNT	GGGTGTGTC	TTntTATTCTG	CCcACTTGGT	500
14201.5	451	ATCTCCATGA	TTGGGCAGTT	GGGTGTGNC	TTntTATTCTG	CCTcCTTGGT	500
14201.13	451	-----	-----	-----	-----	-----	500
		510	520	530	540	550	
Hsp 90	501	GGCAGAGAAA	GTGGTTGTGA	TCAGAAAGCA	CAACGATGAT	GAacAGTATG	550
14201	501	-----	-----	-----	-----	-----	550
14201.3	501	GGCAGAGAAA	NNT.....	.....	.....	.....	550
14201.5	501	GGCAGAGAAA	GTNGTTGTGA	TCA.....	.....	.....	550
14201.13	501	-----	-----	-----	-----	TT GAGnAGTATG	550
		560	570	580	590	600	
Hsp 90	551	cTtgGgAGTc	TtCTGcTGGA	GGTTCCCTCA	CTgtGCGTGC	TGACCATGGT	600
14201	551	-----	-----	-----	-----	-----	600
14201.3	551	.....	.....	.....	.....	.....	600
14201.5	551	.....	.....	.....	.....	.....	600
14201.13	551	-TcnGnAGT-	TaCTGnTGGA	GGTTCCCTCA	CTnnGCGTGC	TGAC-ATGGT	600
		610	620	630	640	650	
Hsp 90	601	GAGCCCATtG	GcAtggGTAC	CaaAGTGATC	CTCCATCTA	AAGAAGATCA	650
14201	601	-----	-----	-----	-----	-----	650
14201.3	601	.....	.....	.....	.....	.....	650
14201.5	601	.....	.....	.....	.....	.....	650
14201.13	601	GAGCCCATnG	GgAgggGTAC	CaAGTGATC	CTCCATCTCA	AAGAAGATCA	650

FIGURE 7B

9/20

	660	670	680	690	700	
Hsp 90	651 GACAGAGTAC	CTAGAaGAGA	GGCGGgTCAA	AGaAGTAGTG	AaGAaGCATT	700
14201	651 -----	-----	-----	-----	-----	700
14201.3	651 .....	.....	.....	.....	.....	700
14201.5	651 .....	.....	.....	.....	.....	700
14201.13	651 GACAGAGTAC	CTAGAnGAGA	GGCGGgTCAA	AGnAGTAGTG	AtGAAnGCATc	700
	710	720	730	740	750	
Hsp 90	701 CTCAGtTCAT	AGGCTATCCC	ATCACCCCTT	aTTTGGAGAA	GGaACGAGAG	750
14201	701 -----	-----	-----	-----	-----	750
14201.3	701 .....	.....	.....	.....	.....	750
14201.5	701 .....	.....	.....	.....	.....	750
14201.13	701 CTCAGAtTCAT	AGGCTATCCC	ATCACCCCTT	nTTTGGAGAA	GGnACGAGAG	750
	760	770	780	790	800	
Hsp 90	751 AAGGAaATTA	GtGATGATGA	GGCAGAGGAA	GAGAAaGGTG	AGAAaGAAGA	800
14201	751 -----	-----	-----	-----	-----	800
14201.3	751 .....	.....	.....	.....	.....	800
14201.5	751 .....	.....	.....	.....	.....	800
14201.13	751 AAGGAnATTA	GnGATGATGA	GGCAGAGGAA	GAGAatGGTG	AGAAtGAAGA	800
	810	820	830	840	850	
Hsp 90	801 GGAAgATAAA	GATGATGAAG	AAAagCCCAA	GATCGAAgAT	GTGGgTTCAg	850
14201	801 -----	-----	-----	-----	-----	850
14201.3	801 .....	.....	.....	.....	.....	850
14201.5	801 .....	.....	.....	.....	.....	850
14201.13	801 GGAnGnTAAc	GATGATGAAG	AAAncCCCAA	GATCGAtGAT	GTGGnTTCAg	850
	860	870	880	890	900	
Hsp 90	851 ATGAGGaaGGA	TGACAGCGGT	aAgGATAAGA	AGAAGAAaAC	TAaGAagATC	900
14201	851 -----	-----	-----	-----	-----	900
14201.3	851 .....	.....	.....	.....	.....	900
14201.5	851 .....	.....	.....	.....	.....	900
14201.13	851 ATGAGGnGGA	TGACAGCGGT	nAnGATAAGA	AGAAGAAaAC	TAnGAnnATC	900
	910	920	930	940	950	
Hsp 90	901 AAAGAGAAAT	ACATTGATCA	GGAAGAACTA	AAACAAGACCA	AGCCTATTTG	950
14201	901 -----	-----	-----	-----	-----	950
14201.3	901 .....	.....	.....	.....	.....	950
14201.5	901 .....	.....	.....	.....	.....	950
14201.13	901 .....	.....	.....	.....	.....	950
	960	970	980	990	1000	
Hsp 90	951 GACCAGAAAC	CCTGATGACA	TCACCCAAAGA	GGAGTATGGA	GAATTCTACA	1000
14201	951 -----	-----	-----	-----	-----	1000
14201.3	951 .....	.....	.....	.....	.....	1000
14201.5	951 .....	.....	.....	.....	.....	1000
14201.13	951 .....	.....	.....	.....	.....	1000

FIGURE 7C

10/20

		1010	1020	1030	1040	1050	
Hsp 90	1001	AGAGCCTCAC	TAATGACTGG	GAAGACCACT	TGGCAGTCAA	GCACTTTCT	1050
14201	1001	-----	-----	-----	-----	-----	1050
14201.3	1001	.....	.....	.....	.....	.....	1050
14201.5	1001	.....	.....	.....	.....	.....	1050
14201.13	1001	.....	.....	.....	.....	.....	1050
		1060	1070	1080	1090	1100	
Hsp 90	1051	GTAGAAGGTC	AGTTGGAATT	CAGGGCATTG	CTATTTATTC	CTCGTCGGGC	1100
14201	1051	-----	-----	-----	-----	-----	1100
14201.3	1051	.....	.....	.....	.....	.....	1100
14201.5	1051	.....	.....	.....	.....	.....	1100
14201.13	1051	.....	.....	.....	.....	.....	1100
		1110	1120	1130	1140	1150	
Hsp 90	1101	TCCCTTGAC	CTTTTGAGA	ACAAGAAGAA	AAAGAACAAAC	ATCAAACCTCT	1150
14201	1101	-----	-----	AAGAA	AAAGAACAAAC	ATCAAACCTCT	1150
14201.3	1101	.....	.....	.....	.....	.....	1150
14201.5	1101	.....	.....	.....	.....	.....	1150
14201.13	1101	.....	.....	.....	.....	.....	1150
		1160	1170	1180	1190	1200	
Hsp 90	1151	ATGTCCGCCG	TGTGTTCATC	ATGGaCAGCT	GTGATGAGTT	GATACCAAGAG	1200
14201	1151	ATGTCCGCCG	TGTGTTCATC	ATGGnCAGCT	GTGATGAGTT	GATACCAAGAG	1200
14201.3	1151	.....	.....	.....	.....	.....	1200
14201.5	1151	.....	.....	.....	.....	.....	1200
14201.13	1151	.....	.....	.....	.....	.....	1200
		1210	1220	1230	1240	1250	
Hsp 90	1201	TATCTCAATT	TTATCCGTGG	TGTGGTTGAC	TcTGAGGAGTC	TGCCCTGAA	1250
14201	1201	TATCTCAATT	TTATCCGTGG	TGTGGTTGAC	TnTGAGGAGTC	TGCCCTGAA	1250
14201.3	1201	.....	.....	.....	.....	.....	1250
14201.5	1201	.....	.....	.....	.....	.....	1250
14201.13	1201	.....	.....	.....	.....	.....	1250
		1260	1270	1280	1290	1300	
Hsp 90	1251	CATCTCCCGa	GAAATGCTCC	AGCAGAGCAA	AATCTTGAAA	GtCATTGCA	1300
14201	1251	CATCTCCCGn	GAAATGCTCC	AGCAGAGCAA	AATCTTGAAA	GgCATTGCA	1300
14201.3	1251	.....	.....	.....	.....	.....	1300
14201.5	1251	.....	.....	.....	.....	.....	1300
14201.13	1251	.....	.....	.....	.....	.....	1300
		1310	1320	1330	1340	1350	
Hsp 90	1301	AAAACATTGT	TAAGaAGTGC	CTTgAGCTCT	TCTCTgAGCT	GGCAGAAAGaC	1350
14201	1301	AAAACATTGT	TAAGnAGTGC	CTTnAGCTCT	TCTCTnAGCT	GGCAGAAAGnC	1350
14201.3	1301	.....	.....	.....	.....	.....	1350
14201.5	1301	.....	.....	.....	.....	.....	1350
14201.13	1301	.....	.....	.....	.....	.....	1350

FIGURE 7D

11/20

	1360	1370	1380	1390	1400	
Hsp 90	1351 AAGGAGAATT	ACAAGAAATT	CTATGAGGCA	TTCTCTAAAA	ATCTCAAGCT	1400
14201	1351 AAGG-GGATT	TCAAGAAATT	CTTGGGG--	-----	-----	1400
14201.3	1351 .....	.....	.....	.....	.....	1400
14201.5	1351 .....	.....	.....	.....	.....	1400
14201.13	1351 .....	.....	.....	.....	.....	1400
	1410	1420	1430	1440	1450	
Hsp 90	1401 TGGAATCCAC	GAAGACTCCA	CTAACCGCCG	CCGCCTGTCT	GAGCTGCTGC	1450
14201	1401 -----	-----	-----	-----	-----	1450
14201.3	1401 .....	.....	.....	.....	.....	1450
14201.5	1401 .....	.....	.....	.....	.....	1450
14201.13	1401 .....	.....	.....	.....	.....	1450
	1460	1470	1480	1490	1500	
Hsp 90	1451 GCTATCATAC	CTCCCAAGTCT	GGAGATGAGA	TGACATCTCT	GTCAGAGTAT	1500
14201	1451 -----	-----	-----	-----	-----	1500
14201.3	1451 .....	.....	.....	.....	.....	1500
14201.5	1451 .....	.....	.....	.....	.....	1500
14201.13	1451 .....	.....	.....	.....	.....	1500
	1510	1520	1530	1540	1550	
Hsp 90	1501 GTTTCTCGCA	TGAAGGGAGAC	ACAGAAAGTCC	ATCTATTACA	TCACTGGTGA	1550
14201	1501 -----	-----	-----	-----	-----	1550
14201.3	1501 .....	.....	.....	.....	.....	1550
14201.5	1501 .....	.....	.....	.....	.....	1550
14201.13	1501 .....	.....	.....	.....	.....	1550
	1560	1570	1580	1590	1600	
Hsp 90	1551 GAGCAAAGAG	CAGGTGGCCA	ACTCAGCTTT	TGTGGAGCGA	GTGCGGAAAC	1600
14201	1551 -----	-----	-----	-----	-----	1600
14201.3	1551 .....	.....	.....	.....	.....	1600
14201.5	1551 .....	.....	.....	.....	.....	1600
14201.13	1551 .....	.....	.....	.....	.....	1600
	1610	1620	1630	1640	1650	
Hsp 90	1601 GGGGCTTCGA	GGTGGTATAT	ATGACCGAGC	CCATTGACGA	GTACTGTGTG	1650
14201	1601 -----	-----	-----	-----	-----	1650
14201.3	1601 .....	.....	.....	.....	.....	1650
14201.5	1601 .....	.....	.....	.....	.....	1650
14201.13	1601 .....	.....	.....	.....	.....	1650

FIGURE 7E

12/20

		1660	1670	1680	1690	1700	
Hsp 90	1651	CAGCAGCTCA	AGGAATTGGA	TGGGAAGAGC	CTGGTCTAG	TTACCAAGGA	1700
14201	1651	-----	-----	-----	-----	-----	1700
14201.3	1651	.....	.....	.....	.....	.....	1700
14201.5	1651	.....	.....	.....	.....	.....	1700
14201.13	1651	.....	.....	.....	.....	.....	1700
		1710	1720	1730	1740	1750	
Hsp 90	1701	GGGTCTGGAG	CTGCCTGAGG	ATGAGGAGGA	GAAGAAGAAG	ATGAAAGAGA	1750
14201	1701	-----	-----	-----	.....	.....	1750
14201.3	1701	.....	.....	.....	.....	.....	1750
14201.5	1701	.....	.....	.....	.....	.....	1750
14201.13	1701	.....	.....	.....	.....	.....	1750
		1760	1770	1780	1790	1800	
Hsp 90	1751	GCAAGGCCAA	GTTTGAGAAC	CTCTGCAAGC	TCATGAAAGA	AATCTTAGAT	1800
14201	1751	.....	.....	.....	.....	.....	1800
14201.3	1751	.....	.....	.....	.....	.....	1800
14201.5	1751	.....	.....	.....	.....	.....	1800
14201.13	1751	.....	.....	.....	.....	.....	1800
		1810	1820	1830	1840	1850	
Hsp 90	1801	AAGAAGGTTG	AGAAGGTGAC	AATCTCCAAT	AGACTTGTT	CTTCACCTTG	1850
14201	1801	.....	.....	.....	.....	.....	1850
14201.3	1801	.....	.....	.....	.....	.....	1850
14201.5	1801	.....	.....	.....	.....	.....	1850
14201.13	1801	.....	.....	.....	.....	.....	1850
		1860	1870	1880	1890	1900	
Hsp 90	1851	CTGCATTGTG	ACCAGCACCT	ACGGCTGGAC	AGCCAATATG	GAGGGATCA	1900
14201	1851	.....	.....	.....	.....	.....	1900
14201.3	1851	.....	.....	.....	.....	.....	1900
14201.5	1851	.....	.....	.....	.....	.....	1900
14201.13	1851	.....	.....	.....	.....	.....	1900
		1910	1920	1930	1940	1950	
Hsp 90	1901	TGAAAGCCCA	GGCCTTCGG	GACAACCTCCA	CCATGGCTA	TATGATGGCC	1950
14201	1901	.....	.....	.....	.....	.....	1950
14201.3	1901	.....	.....	.....	.....	.....	1950
14201.5	1901	.....	.....	.....	.....	.....	1950
14201.13	1901	.....	.....	.....	.....	.....	1950
		1960	1970	1980	1990	2000	
Hsp 90	1951	AAAAAGCACC	TGGAGATCAA	CCCTGACCAC	CCCATTGTGG	AGACGGCTGCG	2000
14201	1951	.....	.....	.....	.....	.....	2000
14201.3	1951	.....	.....	.....	.....	.....	2000
14201.5	1951	.....	.....	.....	.....	.....	2000
14201.13	1951	.....	.....	.....	.....	.....	2000

FIGURE 7F

		2010	2020	2030	2040	2050	
Hsp 90	2001	GCAGAAGGCT	GAGGCCGACA	AGAATGATAA	GGCAGTTAAG	GACCTGGTGG	2050
14201	2001	.....	.....	.....	.....	.....	2050
14201.3	2001	.....	.....	.....	.....	.....	2050
14201.5	2001	.....	.....	.....	.....	.....	2050
14201.13	2001	.....	.....	.....	.....	.....	2050
		2060	2070	2080	2090	2100	
Hsp 90	2051	TGCTGCTGTT	TGAAACCGCC	CTGCTATCTT	CTGGCTTTC	CCTTGAGGAT	2100
14201	2051	.....	.....	.....	.....	.....	2100
14201.3	2051	.....	.....	.....	.....	.....	2100
14201.5	2051	.....	.....	.....	.....	.....	2100
14201.13	2051	.....	.....	.....	.....	.....	2100
		2110	2120	2130	2140	2150	
Hsp 90	2101	CCCCAGACCC	ACTCCAACCG	CATCTATCGC	ATGATCAAGC	TAGGTCTAGG	2150
14201	2101	.....	.....	.....	.....	.....	2150
14201.3	2101	.....	.....	.....	.....	.....	2150
14201.5	2101	.....	.....	.....	.....	.....	2150
14201.13	2101	.....	.....	.....	.....	.....	2150
		2160	2170	2180	2190	2200	
Hsp 90	2151	TATTGATGAA	GATGAAGTGG	CAGCAGAGGA	ACCCAATGCT	GCAGTTCCTG	2200
14201	2151	.....	.....	.....	.....	.....	2200
14201.3	2151	.....	.....	.....	.....	.....	2200
14201.5	2151	.....	.....	.....	.....	.....	2200
14201.13	2151	.....	.....	.....	.....	.....	2200
		2210	2220	2230	2240	2250	
Hsp 90	2201	ATGAGATCCC	CCCTCTCGAG	GGCGATGAGG	ATGCGTCTCG	CATGGAAGAA	2250
14201	2201	.....	.....	.....	.....	.....	2250
14201.3	2201	.....	.....	.....	.....	.....	2250
14201.5	2201	.....	.....	.....	.....	.....	2250
14201.13	2201	.....	.....	.....	.....	.....	2250
		2260	2270	2280	2290	2300	
Hsp 90	2251	GTCGATTAGG	TTAGGAGTTC	ATAGTTGGAA	AACTTGTGCC	CTTGTATACT	2300
14201	2251	.....	.....	.....	.....	.....	2300
14201.3	2251	.....	.....	.....	.....	.....	2300
14201.5	2251	.....	.....	.....	.....	.....	2300
14201.13	2251	.....	.....	.....	.....	.....	2300
		2310	2320	2330	2340	2350	
Hsp 90	2301	GTCCCCATGG	GCTCCCACTG	CAGCCTCGAG	TGCCCTGTC	CCACCTGGCT	2350
14201	2301	.....	.....	.....	.....	.....	2350
14201.3	2301	.....	.....	.....	.....	.....	2350
14201.5	2301	.....	.....	.....	.....	.....	2350
14201.13	2301	.....	.....	.....	.....	.....	2350

## FIGURE 7G

	2360	2370	2380	2390	2400	
Hsp 90	2351	CCCCCTGCTG	GTGTCTAGTG	TTTTTTCCC	TCTCCTGTCC	TTGTGTTGAA
14201	2351	.....	.....	.....	.....	2400
14201.3	2351	.....	.....	.....	.....	2400
14201.5	2351	.....	.....	.....	.....	2400
14201.13	2351	.....	.....	.....	.....	2400
	2410	2420	2430	2440	2450	
Hsp 90	2401	GGCAGTAAAC	TAAGGGTGTC	AAGCCCCATT	CCCTCTCTAC	TCTTGACAGC
14201	2401	.....	.....	.....	.....	2450
14201.3	2401	.....	.....	.....	.....	2450
14201.5	2401	.....	.....	.....	.....	2450
14201.13	2401	.....	.....	.....	.....	2450
	2460	2470	2480	2490	2500	
Hsp 90	2451	AGGATTGGAT	GTGTGTATT	GTGGTTTATT	TTATTTCTT	CATTTTGTTC
14201	2451	.....	.....	.....	.....	2500
14201.3	2451	.....	.....	.....	.....	2500
14201.5	2451	.....	.....	.....	.....	2500
14201.13	2451	.....	.....	.....	.....	2500
	2510	2520	2530	2540	2550	
Hsp 90	2501	TGAAATTAAA	GTATGCAAAA	TAAAGAATAT	GCCGTTTTA	TAC.....
14201	2501	.....	.....	.....	.....	2550
14201.3	2501	.....	.....	.....	.....	2550
14201.5	2501	.....	.....	.....	.....	2550
14201.13	2501	.....	.....	.....	.....	2550

FIGURE 7H

15/20

	10	20	30	40	50	
caphepsin	1 TCCGGCAACG	CCAACCGCTC	CGCTGCGCGC	AGGCTGGGCT	GCAGGCTCTC	50
87058	1 -----	-----	-----	-----	-----	50
87058.6	1 -----	-----	-----	-----	-----	50
87058.8	1 -----	-----	-----	-----	-----	50
87058.16	1 -----	-----	-----	-----	-----	50
	60	70	80	90	100	
caphepsin	51 GGCTGCAGCG	CTGGGCTGGT	GTGCAGTGGT	GCGACCACGG	CTCACGGCAG	100
87058	51 -----	-----	-----	-----	-----	100
87058.6	51 -----	-----	-----	-----	-----	100
87058.8	51 -----	-----	-----	-----	-----	100
87058.16	51 -----NCN	GGTGAGNAT	TCGGACNAGT	CCGAAAACGT	CCGGCAAGTC	100
	110	120	130	140	150	
caphepsin	101 CCTCAGCCAC	CCAGATGTAA	GCGATCTGGT	TCCCACCTCA	GCCTCCCGAG	150
87058	101 -----	-----	-----	-----	-----	150
87058.6	101 -----	-----	-----	-----	-----	150
87058.8	101 -----	-----	-----	-----	-----	150
87058.16	101 ACCCGCTCCG	CTGNCGCAG	GCTGGGNTGC	AGGCTCTCGG	NTGCAGNGCT	150
	160	170	180	190	200	
caphepsin	151 TAGTGGATCT	AGGATCCGGC	TTCCAACATG	TGGCAGCCT	GGGCCTCCCT	200
87058	151 -----	-----	-----	-----	-----	200
87058.6	151 -----	-----	-----	-----	-----	200
87058.8	151 -----	-----	-----	-----	-----	200
87058.16	151 GGGTGGATCT	AGGATCCGGC	TTCCAACATG	TGGCAGCCT	GGGCCTCCCT	200
	210	220	230	240	250	
caphepsin	201 CTGcTGCTG	CTGGTGTGG	CCAATGCCCG	GAGcAGGcCC	TCTTTCATC	250
87058	201 -----	-----	-----	-----	-----	250
87058.6	201 -----	-----	-----	-----	-----	250
87058.8	201 -----	-----	-----	-----	-----	250
87058.16	201 CTGnTGCTG	CTGGTGTGG	aCAATGCCCG	GAGgAGGnCC	TCTTTCATC	250
	260	270	280	290	300	
caphepsin	251 CCCTGTGGA	TGAGCTGGTC	AaCTATGTCA	ACAAACGGAA	TACCACTGTGG	300
87058	251 -----	-----	-----	-----	-----	300
87058.6	251 -----	-----	-----	-----	-----	300
87058.8	251 -----	-----	-----	-----	-----	300
87058.16	251 CCCTGTGGA	TGAGCTGGTC	AnCTATGTCA	ACAAACGGAA	TACCACTGTGG	300

FIGURE 8A

16/20

	310	320	330	340	350	
caphepsin	301 cAGGCCGGaA	ACAACCTCTA	CAACGTGGAC	ATGAGCTACT	TGAAAGGGcT	350
87058	301 -----	-----	-----	-----	-----	350
87058.6	301 -----	-----	-----	-----	-----	350
87058.8	301 -----	-----	-----	-----	-----	350
87058.16	301 nAGGCCGGgA	ACAACCTCTA	CAACGTGGAC	ATGAGCTACT	TGAnAGGGhT	350
	360	370	380	390	400	
caphepsin	351 ATGTGGTACC	TTCCCTGGGTG	GGCCCAAGCC	ACCCCAAGAGA	GTTATGTTTA	400
87058	351 -----	-----	-----	-----	-----	400
87058.6	351 -----	-----	-----	-----	-----	400
87058.8	351 --GaGGTACC	TTCCCTGGGTG	GGCCCAAGCC	ACCCCAAGAGA	GTTATGTTTA	400
87058.16	351 ATGTGGTACC	TTCCCTGGGTG	GGCCCAAGCC	ACCCCAAGAGA	GTTNTGTTTA	400
	410	420	430	440	450	
caphepsin	401 CCGAGGACCT	GAAGCTGCCT	GCAAGCTTCG	ATGCACGGGA	ACAATGGCCA	450
87058	401 -----	-----	-----	-----	-----	450
87058.6	401 -----	-----	-----	-----	-----	450
87058.8	401 CCGAGGACCT	GAAGCTGCCT	GCAAGCTTCG	ATGCACGGGA	ACAATGGCCA	450
87058.16	401 CCGAGGACCT	GANGCTGCCT	GCAAGCTTCG	AaGgACGGGA	ACAATGGCCA	450
	460	470	480	490	500	
caphepsin	451 CAGTGTCCC	CCATCAAAGA	GATCAGAGAC	CAGGGCTCCT	GIGGCTCCTG	500
87058	451 -----	-----	-----	-----	-----	500
87058.6	451 -----	-----	-----	-----	-----	500
87058.8	451 CAGTGTCCC	CCATCAAAGA	GATCAGAGAC	CAGGGNTCCT	GTGGCTCCTG	500
87058.16	451 CAGTGTCCC	CCATCAAAGA	GATCAGAGAN	CAGGGCTCCT	GTGGNTCCTG	500
	510	520	530	540	550	
caphepsin	501 CTGGGCCTTC	GGGGCTGTGG	AAGCCATCTC	TGACCGGATC	TGCATCCACA	550
87058	501 -----	-----	-----	-----	-----	550
87058.6	501 -----	-----	-----	-----	-----	550
87058.8	501 CTGGGCCTTC	GGGGCTGTGG	AAGCCATCTC	TGACCGGATC	TGNATCCACA	550
87058.16	501 CTGGGCCTTC	GGGGCTGTGG	AAGNCATCTC	TGACCGGATC	TGCATCCACA	550
	560	570	580	590	600	
caphepsin	551 CCAATGCGCA	CGTCAGCGTG	GAGGTGTCGG	CGGAGGACCT	GCTCACATGC	600
87058	551 -----	-----	-----	-----	-----	600
87058.6	551 -----	-----	-----	-----	-----	600
87058.8	551 CCAATGCGCA	CGTCAGCGTG	GAGGTGTCGG	CGGAGGAC-T	GCTCACATGC	600
87058.16	551 CCAATGNGCA	CGTCAGCGTG	GtGGTGTGG	NGGAGGACCT	GaTCACCTNT	600
	610	620	630	640	650	
caphepsin	601 TGTGGCAGCA	TGTGTGGGGA	CGGCTGTAAT	GGTGGCTATC	CTGCTGAAGC	650
87058	601 -----	-----	-----	-----	-----	650
87058.6	601 -----	-----	-----	-----	-----	650
87058.8	601 TGTGGCAGNA	TGTGTGGGGA	CGGCTGTAAT	GGTGGCTATC	CTGCTGAAGC	650
87058.16	601 TGTGGTAGCA	TGTGTGGGGA	CGGCTGTAAT	GGTGGtTATC	CTGNTGAAGC	650

FIGURE 8B

17/20

		660	670	680	690	700	
caphepsin	651	TTGGAACCTTC	TGGACAAGAA	AAGGCCTGGT	TTCTGGTGGC	CTCTATGAAT	700
87058	651	-----	-----	-----	-----	-----	700
87058.6	651	TTGGAACCTTC	TGGACAAGAA	AAGGCCTGGT	TTCTGGTGGC	CTCTATGAAT	700
87058.8	651	TTGGNACTTC	TGGACAAGAA	AAGGCCTGGT	TTCTGGTGGC	CTCTATGANT	700
87058.16	651	TNgggNCTTC	TNagaAAGAA	AAGGctNGtT	TT--GGTGGC	CT-TATGAcT	700
		710	720	730	740	750	
caphepsin	701	CCCATGTAGG	GTGCAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCAACGTC	750
87058	701	-----	-----	-----	-----	-----	750
87058.6	701	CCCATGTAGG	GTGCAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCAACGTC	750
87058.8	701	CCCATGTAGG	GTGTAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCAACGTC	750
87058.16	701	CCCATGT...	.....	.....	.....	.....	750
		760	770	780	790	800	
caphepsin	751	AACGGCTCCC	GGCCCCCATG	CACGGGGGAG	GGAGATAACCC	CCAAGTGTAG	800
87058	751	-----	-----	-----	-----	-----	800
87058.6	751	AACGGCTCCC	GGCCCCCATG	CACGGGGGAG	GGAGATAACCC	CCAAGTGTAG	800
87058.8	751	AACGGtTCCC	GGgCCCCATG	CACGGNGGAG	GGAGATAACCC	CCAAGTGTAA	800
87058.16	751	.....	.....	.....	.....	.....	800
		810	820	830	840	850	
caphepsin	801	CAAGATCTGT	GAGCCTGGCT	ACAGCCCGAC	CTACAAACAG	GACAAGCACT	850
87058	801	-----	-----	-----	-----	-----	850
87058.6	801	CAAGATCTGT	GAGCCTGGCT	ACAGCCCGAC	CTACAAACAG	GACAAGCACT	850
87058.8	801	CAAGATCTGT	GAGCCTGGgT	ACAGtCCcga	CcACAAACAG	GAaAAGCACT	850
87058.16	801	.....	.....	.....	.....	.....	850
		860	870	880	890	900	
caphepsin	851	ACGGATAACAA	TTCCTACAGC	GTCTCCAATA	GCGAGAAGGA	CATCATGGCC	900
87058	851	-----	-----	-----	-----	-----	900
87058.6	851	ACGGATAACAA	TTCCTACAGC	GTCTCCAATA	GCGAGAAGGA	CATCATGGCC	900
87058.8	851	ACGGATAACAA	TTCCT-CAGN	GTCTCCAATA	GtGAGAAGGA	CATCAT-GCC	900
87058.16	851	.....	.....	.....	.....	.....	900
		910	920	930	940	950	
caphepsin	901	GAGATCTACA	AAAACGGCCC	CGTGGAGGGA	GCTTTCTCTG	TGTATTCCGA	950
87058	901	-----	-----	-----	-----	-----	950
87058.6	901	GAGATCTACA	AAAACGGCCC	CGTGGAGGGA	GCTTTCTCTG	TGTATTCCGA	950
87058.8	901	GAGATCTACA	ATAACGGC..	.....	.....	.....	950
87058.16	901	.....	.....	.....	.....	.....	950
		960	970	980	990	1000	
caphepsin	951	CTTCCTGCTC	TACAAGTCAG	GAGTGTACCA	ACACGTCA	GGAGAGATGA	1000
87058	951	-----	-----	-----	-----	-----	1000
87058.6	951	CTTCCTGCTC	TACAAGTCAG	GAGTGTACCA	ACACGTCA	GGAGAGATGA	1000
87058.8	951	.....	.....	.....	.....	.....	1000
87058.16	951	.....	.....	.....	.....	.....	1000

FIGURE 8C

		1010	1020	1030	1040	1050	
caphepsin	1001	TGGGTGCCA	TGCCATCCGC	ATCCTGGGCT	GGGGAGTGGA	GAATGGCACA	1050
87058	1001	-----	-----	-----	-----	-----	1050
87058.6	1001	TGGGTGCCA	TGCCATCCGC	ATCCTGGGCT	GGGGAGTGGA	GAATGGCACA	1050
87058.8	1001	.....	.....	.....	.....	.....	1050
87058.16	1001	.....	.....	.....	.....	.....	1050
		1060	1070	1080	1090	1100	
caphepsin	1051	ccCTACTGGC	TGGTTGCCA	CTCCTGGAAC	ACTGACTGGG	GTGACAATGG	1100
87058	1051	-----cGg	cagacGCCAA	CTCCTGGAAC	ACTGACTGGG	GTGACAATGG	1100
87058.6	1051	aCCTACTGGC	TGGTTGgCAA	CTCCTGGAAC	ACTGACTGGG	GTGACAATGG	1100
87058.8	1051	.....	.....	.....	.....	.....	1100
87058.16	1051	.....	.....	.....	.....	.....	1100
		1110	1120	1130	1140	1150	
caphepsin	1101	CTTCTTAAA	ATACTCAGAG	GACAGGATCA	CTGTGGAATC	GAATCAGAAG	1150
87058	1101	CTTCTTAAA	ATACTCAGAG	GACAGGTTCA	CTGTGGAATC	GAATCAGAAG	1150
87058.6	1101	gTTC-----	-----	-----	-----	-----	1150
87058.8	1101	.....	.....	.....	.....	.....	1150
87058.16	1101	.....	.....	.....	.....	.....	1150
		1160	1170	1180	1190	1200	
caphepsin	1151	TGGTGGCTGG	AATTCACGC	ACCGATCAGT	ACTGGGAAAA	GATCTAATCT	1200
87058	1151	TGGTGGCTGG	AATTCACGC	ACCGTTCA	ACTGGGAAAA	GNTCTAATCT	1200
87058.6	1151	-----	-----	-----	-----	-----	1200
87058.8	1151	.....	.....	.....	.....	.....	1200
87058.16	1151	.....	.....	.....	.....	.....	1200
		1210	1220	1230	1240	1250	
caphepsin	1201	GCCGTGGGCC	TGTCGTGCCA	GTCCCTGGGG	CGAGATCGGG	GTAGAAATGC	1250
87058	1201	GCCGTGGGCC	TNTCGTGCCA	GTCCCTGGGG	CGAGATGGGG	GTAGAAATGC	1250
87058.6	1201	-----	-----	-----	-----	-----	1250
87058.8	1201	.....	.....	.....	.....	.....	1250
87058.16	1201	.....	.....	.....	.....	.....	1250
		1260	1270	1280	1290	1300	
caphepsin	1251	ATTTTATTCT	TTAAGTTCAC	GTAAGATACA	AGTTTCAGGc	AGGGTCTqAA	1300
87058	1251	ATTTTATTCT	TTAAGTTCAC	GTAAGATACA	AGTTTCAGaC	AGGGTCTnAA	1300
87058.6	1251	.....	.....	.....	.....	.....	1300
87058.8	1251	.....	.....	.....	.....	.....	1300
87058.16	1251	.....	.....	.....	.....	.....	1300
		1310	1320	1330	1340	1350	
caphepsin	1301	GGaCTGGaTT	gGCCAAACAT	CAGACCTGTC	TTCCAAGGAG	ACCAAGTCCT	1350
87058	1301	GGcCTGGnTT	nGCCAAAnAT	CAGACCTGT	.....	.....	1350
87058.6	1301	.....	.....	.....	.....	.....	1350
87058.8	1301	.....	.....	.....	.....	.....	1350
87058.16	1301	.....	.....	.....	.....	.....	1350

FIGURE 8D

		1360	1370	1380	1390	1400	
caphepsin	1351	GGCTACATCC	CAGCCTGTGG	TTACAGTGCA	GACAGGCCAT	GTGAGCCACC	1400
87058	1351	.....	.....	.....	.....	.....	1400
87058.6	1351	.....	.....	.....	.....	.....	1400
87058.8	1351	.....	.....	.....	.....	.....	1400
87058.16	1351	.....	.....	.....	.....	.....	1400
		1410	1420	1430	1440	1450	
caphepsin	1401	GCTGCCAGCA	CAGAGCGTCC	TTCCCCCTGT	AGACTAGTGC	CGTGGGAGTA	1450
87058	1401	.....	.....	.....	.....	.....	1450
87058.6	1401	.....	.....	.....	.....	.....	1450
87058.8	1401	.....	.....	.....	.....	.....	1450
87058.16	1401	.....	.....	.....	.....	.....	1450
		1460	1470	1480	1490	1500	
caphepsin	1451	CCTGCTGCC	AGCTGCTGTG	GCCCCCTCCG	TGATCCATCC	ATCTCCAGGG	1500
87058	1451	.....	.....	.....	.....	.....	1500
87058.6	1451	.....	.....	.....	.....	.....	1500
87058.8	1451	.....	.....	.....	.....	.....	1500
87058.16	1451	.....	.....	.....	.....	.....	1500
		1510	1520	1530	1540	1550	
caphepsin	1501	AGCAAGACAG	AGACCCAGGA	TGGAAAGCGG	AGTTCTAAC	AGGATGAAAG	1550
87058	1501	.....	.....	.....	.....	.....	1550
87058.6	1501	.....	.....	.....	.....	.....	1550
87058.8	1501	.....	.....	.....	.....	.....	1550
87058.16	1501	.....	.....	.....	.....	.....	1550
		1560	1570	1580	1590	1600	
caphepsin	1551	TTCCCCCATC	AGTTCCCCCA	GTACCTCCAA	GCAAGTAGCT	TTCCACATTT	1600
87058	1551	.....	.....	.....	.....	.....	1600
87058.6	1551	.....	.....	.....	.....	.....	1600
87058.8	1551	.....	.....	.....	.....	.....	1600
87058.16	1551	.....	.....	.....	.....	.....	1600
		1610	1620	1630	1640	1650	
caphepsin	1601	GTCACAGAAA	TCAGAGGAGA	GATGGTGTG	GGAGCCCTTT	GGAGAACGCC	1650
87058	1601	.....	.....	.....	.....	.....	1650
87058.6	1601	.....	.....	.....	.....	.....	1650
87058.8	1601	.....	.....	.....	.....	.....	1650
87058.16	1601	.....	.....	.....	.....	.....	1650

FIGURE 8E

20/20

		1660	1670	1680	1690	1700	
caphepsin	1651	AGTCTCCAGG	TCCCCCTGCA	TCTATCGAGT	TTGCAATGTC	ACAAACCTCTC	1700
87058	1651	.....	.....	.....	.....	.....	1700
87058.6	1651	.....	.....	.....	.....	.....	1700
87058.8	1651	.....	.....	.....	.....	.....	1700
87058.16	1651	.....	.....	.....	.....	.....	1700
		1710	1720	1730	1740	1750	
caphepsin	1701	TGATCTTGTG	CTCAGCATGA	TTCTTTAATA	GAAGTTTAT	TTTTCGTGCA	1750
87058	1701	.....	.....	.....	.....	.....	1750
87058.6	1701	.....	.....	.....	.....	.....	1750
87058.8	1701	.....	.....	.....	.....	.....	1750
87058.16	1701	.....	.....	.....	.....	.....	1750
		1760	1770	1780	1790	1800	
caphepsin	1751	CTCTGCTAAT	CATGTGGGTG	AGCCAGTGGA	ACAGCGGGAG	CCTGTGCTGG	1800
87058	1751	.....	.....	.....	.....	.....	1800
87058.6	1751	.....	.....	.....	.....	.....	1800
87058.8	1751	.....	.....	.....	.....	.....	1800
87058.16	1751	.....	.....	.....	.....	.....	1800
		1810	1820	1830	1840	1850	
caphepsin	1801	TTTGCAGATT	GCCTCCTAAT	GACGCCGGCTC	AAAAGGAAAC	CAAGTGGTCA	1850
87058	1801	.....	.....	.....	.....	.....	1850
87058.6	1801	.....	.....	.....	.....	.....	1850
87058.8	1801	.....	.....	.....	.....	.....	1850
87058.16	1801	.....	.....	.....	.....	.....	1850
		1860	1870	1880	1890	1900	
caphepsin	1851	GGAGTTGTTT	CTGACCCACT	GATCTCTACT	ACCACAAGGA	AAATAGTTA	1900
87058	1851	.....	.....	.....	.....	.....	1900
87058.6	1851	.....	.....	.....	.....	.....	1900
87058.8	1851	.....	.....	.....	.....	.....	1900
87058.16	1851	.....	.....	.....	.....	.....	1900
		1910	1920	1930	1940	1950	
caphepsin	1901	GGAGAAACCA	GCTTTTACTG	TTTTGAAAAA	ATTACAGCTT	CACCCGTGCA	1950
87058	1901	.....	.....	.....	.....	.....	1950
87058.6	1901	.....	.....	.....	.....	.....	1950
87058.8	1901	.....	.....	.....	.....	.....	1950
87058.16	1901	.....	.....	.....	.....	.....	1950
		1960	1970	1980	1990	2000	
caphepsin	1951	AGTTAACAAAG	GAATGCCTGT	GCCAATAAAA	GGTTTCTCCA	ACTTGA....	2000
87058	1951	.....	.....	.....	.....	.....	2000
87058.6	1951	.....	.....	.....	.....	.....	2000
87058.8	1951	.....	.....	.....	.....	.....	2000
87058.16	1951	.....	.....	.....	.....	.....	2000

## FIGURE 8F

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/08501

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 C12Q1/68 C12P19/34 C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS. EDITOR INNIS M.; PUBLISHER ACADEMIC, 1990, SAN DIEGO, CALIF., pages 219-27, XP002015609</p> <p>OCHMAN, H. ET AL: "Amplification of flanking sequences by inverse PCR" see whole article</p> <p>---</p> <p>BIOTECHNIQUES, vol. 18, no. 5, May 1995, pages 762-64, XP000509322</p> <p>COOLIDGE C ET AL: "Run-around PCR: A novel way to create duplications using polymerase chain reaction" see the whole document</p> <p>---</p> <p>-/-</p>	1-8
X		1-8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

10 October 1996

Date of mailing of the international search report

25.10.96

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 cpo nl,  
 Fax: (+31-70) 340-3016

## Authorized officer

Osborne, H

## INTERNATIONAL SEARCH REPORT

International Application No  
PL./US 96/08501

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 268, no. 12, 1993, pages 8842-50, XP000604943 LEE, D. ET AL.: "Molecular cloning and genomic organization of a gene for luciferin-binding protein from dinoflagellate <i>Gonyaulax polyedra</i> " see the whole document ---	1-8
X	US,A,4 994 370 (SILVER) 19 February 1991 see the whole document ---	1-8
X	JOURNAL OF VIROLOGICAL METHODS, vol. 49, no. 3, January 1994, pages 269-84, XP000606337 TSUEI D-J ET AL: "Inverse polymerase chain reaction for cloning cellular sequences adjacent to integrated hepatitis b virus in hepatocellular carcinomas" see the whole document ---	1-8
X	WO,A,90 14423 (THE INFERGENE CO.) 29 November 1990 see page 19 ---	1-8
A	WO,A,93 12257 (HYBRITECH INC) 24 June 1993 see the whole document ---	1-8
A	NUCLEIC ACIDS RESEARCH, vol. 19, 1991, pages 3055-60, XP002015610 PARKER J. ET AL: "Walking PCR" cited in the application -----	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/08501

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-4994370	19-02-91	NONE		
WO-A-9014423	29-11-90	NONE		
WO-A-9312257	24-06-93	AU-A-	3274793	19-07-93
		US-A-	5512463	30-04-96